Document:

SUPPLY AGREEMENT

 Exhibit 4.15 
 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN 
 THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN

 OMITTED AND FILED SEPARATELY WITH THE 
 SECURITIES AND EXCHANGE COMMISSION PURSUANT TO 
 RULE 24B-2 OF THE SECURITIES EXCHANGE

 ACT OF 1934, AS AMENDED 
 SUPPLY AGREEMENT 
 This Supply Agreement (the “Agreement”) is made and entered into effective as of
December 19, 2005 (the “Effective Date”) by and between GPC Biotech AG, a German corporation, having its place of business at Fraunhoferstrasse 20, 82152 Martinsried/Munich, Germany (“GPC Biotech”); and
Pharmion GmbH, a Swiss limited liability company and wholly-owned subsidiary of Pharmion Corporation, a Delaware corporation, having a place of business at Aeschenvorstadt 71, 4051 Basel, Switzerland (“Licensee”). GPC Biotech and
Licensee are sometimes referred to herein individually as a “Party” and collectively as the “Parties.” 
 RECITALS 
 WHEREAS, the Parties have entered into a Co-Development and License Agreement of even date herewith (the
“License Agreement”), pursuant to which GPC Biotech grants a license to Licensee, and Licensee obtains a license, to Develop and Commercialize the Licensed Product (each as defined therein); and 
 WHEREAS, in accordance with the terms of the License Agreement, the Parties are required to enter into an agreement providing for the supply by
GPC Biotech to Licensee of all of Licensee’s requirements of the Licensed Product; and 
 WHEREAS, GPC Biotech desires to supply
the Licensed Product to Licensee, and Licensee desires to purchase the Licensed Product, all on the terms and conditions set forth below. 
 NOW, THEREFORE, in consideration of the foregoing premises, the mutual promises and covenants of the Parties contained herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
the Parties hereto, intending to be legally bound, do hereby agree as follows: 
 ARTICLE I 
 DEFINITIONS 
 Unless otherwise
specifically provided herein, the following terms shall have the following meanings: 
 1.1 “Affiliate” shall mean, with
respect to a Party, any Person that, directly or indirectly, through one or more intermediaries, controls, is controlled by or is under common control with such Party. For purposes of this definition, “control” and, with correlative
meanings, the terms “controlled by” and “under common control with” shall mean (a) the possession, directly or indirectly, of the power to direct the management or policies of a business entity, whether through the ownership
of voting securities, by contract relating to voting rights or corporate governance, or otherwise, or (b) the ownership, directly or indirectly, of at least fifty percent (50%) of the voting securities or other ownership interest of a
business entity (or, with respect to a limited partnership or other similar entity, its general partner or controlling entity). 
  

 1 

 1.2 “Agreement” shall have the meaning set forth in the preamble to this Agreement.

 1.3 “API” shall mean the Licensed Compound as defined in the License Agreement. 
 1.4 “API Facility” shall mean the Manufacturing facility of the API Subcontractor. 
 1.5 “API Subcontractor” shall mean, as of the Effective Date, Johnson Matthey Inc. or any other Person appointed by GPC Biotech
thereafter and approved by Licensee in writing to supply API, which approval shall not be unreasonably withheld or delayed. 
 1.6
“Applicable Law” shall mean applicable laws, rules and regulations, including any rules, regulations, guidelines or other requirements of the Regulatory Authorities, that may be in effect from time to time. 
 1.7 “Arbitration Rules” shall have the meaning set forth in Section 9.11.2. 
 1.8 “Breaching Party” shall have the meaning set forth in Section 8.2. 
 1.9 “Business Day” shall mean a day other than a Saturday or Sunday on which banking institutions in Munich, Germany are open for
business. 
 1.10 “Calendar Quarter” shall mean each successive period of three (3) calendar months commencing on
January 1, April 1, July 1 and October 1. 
 1.11 “Calendar Year” shall mean each successive
period of twelve (12) calendar months commencing on January 1 and ending on December 31. 
 1.12
“cGMP” shall mean (a) the current good manufacturing practices for the methods used in, and the facilities and controls used for, the Manufacture of the Licensed Product promulgated by any Regulatory Authority including,
without limitation, US cGMP, the EU Good Manufacturing Guidelines, the International Conference on Harmonization Guidelines and any other applicable laws, guidelines and/or regulations, together with the latest FDA and other applicable guidance
documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time. 
 1.13
“Claims” shall have the meaning set forth in Section 7.1. 
 1.14 “CMC Sections” shall mean the
Chemistry, Manufacturing and Controls sections of any Regulatory Documentation, including all information included therein. 
 1.15
“Complaining Party” shall have the meaning set forth in Section 8.2. 
 1.16 “Dispute” shall have the
meaning set forth in Section 9.11.1. 
 1.17 “Distributor” shall have the meaning set forth in the License Agreement.

  

 2 

 1.18 “Drug Master File” shall have the meaning set forth in the License Agreement.

 1.19 “Effective Date” shall mean the effective date of this Agreement as set forth in the preamble to this Agreement.

 1.20 “Exploitation” shall have the meaning set forth in the License Agreement. 
 1.21 “Facilities” shall mean (a) the API Facility, (b) the Finishing Facility, and (c) any Manufacturing facility of GPC
Biotech or its Affiliates. 
 1.22 “FDA” shall mean the United States Food and Drug Administration and any successor agency
thereto. 
 1.23 “FFDCA” shall mean the United States Federal Food, Drug, and Cosmetic Act, as amended from time to time.

 1.24 “Finishing Facility” shall mean the Manufacturing facility of the Finishing Subcontractor or the Manufacturing
facility of GPC Biotech or its Affiliate, as determined by GPC Biotech. 
 1.25 “Finishing Subcontractor” shall mean, as of
the Effective Date, [...***...], or any other Person appointed by GPC Biotech thereafter to supply Licensed Product in bulk capsule form, and approved by Licensee in writing, which approval shall not be unreasonably withheld or delayed.

 1.26 “Forecast(s)” shall have the meaning set forth in Section 2.2.1. 
 1.27 “Full Product Batch” shall mean a specific quantity of Licensed Product equal to approximately 480,000 units comprised of
approximately [...***...] units of [...***...] capsules and approximately [...***...] units of [...***...] capsules. 
 1.28 “GPC Biotech” shall have the meaning set forth in the preamble to this Agreement. 
 1.29
“Indemnification Claim Notice” shall have the meaning set forth in Section 7.3. 
 1.30 “Indemnified
Party” shall have the meaning set forth in Section 7.3. 
 1.31 “Initial Forecast” shall have the meaning set
forth in Section 2.2.1. 
 1.32 “Joint Manufacturing Committee” or “JMC” shall have the meaning set forth in
Section 2.1.4. 
 1.33 “License Agreement” shall have the meaning set forth in the first recital to this Agreement.

  

	***	Confidential Treatment Requested 

  

 3 

 1.34 “Licensed Product” shall mean the “Licensed Product” as defined in the
License Agreement that has been Manufactured by or on behalf of GPC Biotech and delivered to Licensee pursuant to the terms of this Agreement. 
 1.35 “Licensee” shall have the meaning set forth in the preamble to this Agreement. 
 1.36 “Licensee
Territory” shall have the meaning set forth in the License Agreement. 
 1.37 “Losses” shall have the meaning set
forth in Section 7.1. 
 1.38 “Major Market Country” shall have the meaning set forth in the License Agreement.

 1.39 “Manufacturing” shall mean all activities, steps and processes relating to the production, manufacture, processing
and holding of the Licensed Product or any intermediate thereof, including stability testing, quality assurance and quality control. The terms “Manufacture” and “Manufactured” refer to the act of Manufacturing.

 1.40 “Manufacturing Cost” shall have the meaning set forth in the License Agreement. 
 1.41 “Manufacturing Process” shall mean any process or step thereof that is necessary or useful for Manufacturing the Licensed Product
or any intermediate thereof as evidenced in the batch records or master batch records. 
 1.42 “Materials” shall mean all
raw materials, excipients, and containers required in connection with the Manufacture of the Licensed Product, excluding API. 
 1.43
“Notice Period” shall have the meaning set forth in Section 8.2. 
 1.44 “Party” and
“Parties” shall have the meaning set forth in the preamble to this Agreement. 
 1.45
“Permits” shall have the meaning set forth in Section 6.1.1. 
 1.46 “Person” shall
mean an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture or other similar
entity or organization, including a government or political subdivision, department or agency of a government. 
 1.47
“Purchase Order” shall mean a written purchase order submitted by Licensee to GPC Biotech in accordance with Section 2.2.2. 
 1.48 “Quality Agreement” shall mean the quality assurance agreement between the Parties to be agreed upon within ninety (90) days of the Effective Date. 
  

 4 

 1.49 “Regulatory Authority” shall mean any applicable supra-national, federal, national,
regional, state, provincial or local regulatory agencies, departments, bureaus, commissions, councils or other government entities regulating or otherwise exercising authority with respect to the Exploitation of the Licensed Product in the Licensee
Territory. 
 1.50 “Regulatory Documentation” shall have the meaning set forth in the License Agreement. 
 1.51 “Reserve Inventory” shall have the meaning set forth in Section 2.1.2. 
 1.52 “Specifications” shall mean the list of tests, references to any analytical procedures and appropriate acceptance criteria
which are numerical limits, ranges or other criteria for tests described in order to establish a set of criteria to which Licensed Product, at any stage of Manufacture, should conform to be considered acceptable for its intended use as agreed to in
writing by the Parties within ninety (90) days of the Effective Date, as such specifications are amended or supplemented from time to time in accordance with the terms hereof. Without limiting the generality of the foregoing, the Specifications
shall be consistent with all applicable Regulatory Documentation filed prior to the Effective Date and shall specify that the Licensed Products, when delivered to Licensee, shall have a minimum remaining shelf life of not less than seventy five
percent (75%) of the maximum shelf life that is available for the Licensed Products at the time of Manufacture. 
 1.53
“Subcontractor” shall mean either the API Subcontractor or the Finishing Subcontractor. 
 1.54 “Sublicensee”
shall have the meaning set forth in the License Agreement. 
 1.55 “Supply Failure” shall have the meaning set forth in
Section 8.5. 
 1.56 “Supply Price,” with respect to any Licensed Product delivered hereunder, shall mean one hundred
and ten percent (110%) of the Manufacturing Costs for such Licensed Product. 
 1.57 “Term” shall have the
meaning set forth in Section 8.1. 
 1.58 “Third Party” shall mean any Person other than GPC Biotech, Licensee and
their respective Affiliates and Sublicensees. 
 1.59 “US cGMP” shall mean current good manufacturing practices for the
methods used in, and the facilities and controls used for, the Manufacture of the Licensed Products, all as set forth from time to time by the FDA pursuant to the FFDCA and the rules and regulations promulgated thereunder (including specifically
Title 21, parts 210 and 211 of the Code of Federal Regulations of the United States). 
  

 5 

 ARTICLE II 
 SUPPLY OF PRODUCT 
 2.1 Purchase and Supply Obligations. Subject to the provisions of this
Agreement, during the Term Licensee shall, and Licensee shall cause its Sublicensees to, purchase one hundred percent (100%) of their requirements of Licensed Product in bulk capsule form according to the Specifications for sale in the Licensee
Territory from GPC Biotech, and GPC Biotech shall Manufacture and supply such quantities of Licensed Product to Licensee. GPC Biotech shall not supply Licensed Products to any Third Party within the Licensee Territory. In the event that GPC Biotech,
at any time during the Term, has reason to believe that it or any Subcontractor will be unable to perform the services hereunder or that there will be a material delay in performance thereof, GPC Biotech shall (without limiting any other obligations
GPC Biotech may have or rights or remedies Licensee may have ) promptly notify Licensee thereof. 
 2.1.1. Subcontracting.
Licensee acknowledges and agrees that GPC Biotech may subcontract or delegate any or all of its obligations hereunder to any Subcontractor; provided that any change in Subcontractors requires Licensee’s prior written consent and such
subcontracting or delegation shall in no way relieve GPC Biotech of its obligations hereunder except to the extent that such obligations are performed by a Subcontractor. GPC Biotech shall ensure that any Subcontractor engaged by GPC Biotech to
Manufacture Licensed Product Manufactures the Licensed Product pursuant to the terms of this Agreement. 
 2.1.2. API and
Materials; Reserve Inventory. GPC Biotech or its Subcontractors shall obtain and provide all API, Materials and equipment required to Manufacture the Licensed Products hereunder. During the Term of this Agreement, GPC Biotech shall maintain, at
its own expense, a reserve inventory of API and capsule shells to be used in the future Manufacturing of Licensed Products (“Reserve Inventory”) in an amount equal to twice Licensee’s Forecast for the then-current Calendar Quarter.
When using Reserve Inventory in order to Manufacture Licensed Products in accordance with this Agreement, GPC Biotech and its Subcontractors shall manage such inventory with its own inventories of API and Materials on a “first expiry, first
out” basis to maximize shelf life and minimize spoilage. GPC Biotech shall properly store all inventories of API and Materials (including such Reserve Inventory) prior to use in accordance with cGMP and the Specifications. 
 2.1.3. Facilities. GPC Biotech shall Manufacture all Licensed Product hereunder only at the Facilities. GPC Biotech shall maintain,
or shall cause its Subcontractors to maintain, at their own expense, the Facilities and all equipment required for the Manufacture of the Licensed Product in a state of repair and operating efficiency consistent with the requirements of cGMP and all
other Applicable Law. 
  

 6 

 2.1.4. Joint Manufacturing Committee. The JEC (as defined in the License
Agreement) will establish a Joint Manufacturing Committee comprising an equal number of representatives of both Parties (the “JMC”). The JMC shall have the overall responsibility for overseeing the Parties’ activities with respect to
the Manufacture of Licensed Product hereunder and, in particular, the JMC shall (a) discuss any proposed changes to the Manufacturing Process or Specifications; (b) oversee and coordinate regulatory activities relating to Manufacturing;
(c) oversee and establish work plans for analytical methods transfer; (d) coordinate product supply activities; and (e) engage in any other activities or assume any other responsibilities delegated to it by the JEC. The JEC will
establish the meeting schedule and decision-making rules that the JMC will follow in carrying out its responsibilities. 
 2.2 Forecasts
and Purchase Orders. 
 2.2.1. Not later than ninety (90) days following the Effective Date, Licensee shall
provide GPC Biotech with a good faith, written forecast of its anticipated requirements of the Licensed Product and proposed delivery dates thereof for the period beginning on the Effective Date and ending six (6) full Calendar Quarters
thereafter (“Initial Forecast”). Not later than thirty (30) days prior to the beginning of the first full Calendar Quarter after the Initial Forecast and each subsequent full Calendar Quarter of the Term, Licensee shall submit
to GPC Biotech a good faith, written forecast of its anticipated requirements of the Licensed Product and proposed delivery dates thereof for such Calendar Quarter and the five (5) Calendar Quarters thereafter (such forecasts, together with the
Initial Forecast, the “Forecasts”) (for example, not later than thirty (30) days prior to the Calendar Quarter that begins April 1, 2007, Licensee shall submit a Forecast covering the period from April 1, 2007 through
September 30, 2008). The quantities of Licensed Product and delivery dates applicable to the first two (2) Calendar Quarters in each Forecast shall constitute a binding obligation of Licensee to purchase and of GPC Biotech to supply such
quantities and shall not be subject to change without the prior written approval of both GPC Biotech and Licensee. 
 2.2.2. Licensee shall order Licensed Product by the issuance of Purchase Orders to GPC Biotech at least one hundred twenty (120) days prior to the delivery date specified in each respective Purchase Order. Each Purchase Order
shall designate the desired quantities of Licensed Product and the delivery date(s) thereof, and each Purchase Order must be consistent with the binding portion of the most recently delivered Forecast and shall constitute a binding commitment by
Licensee to order from GPC Biotech and by GPC Biotech to deliver to Licensee when placed. All Purchase Orders shall be for Full Product Batch quantities of Licensed Product or integral multiples thereof. 
 2.2.3. GPC Biotech shall confirm acceptance of each Purchase Order submitted in accordance with Section 2.2.2 within thirty
(30) days after receipt thereof and shall use commercially reasonable efforts to deliver 
  

 7 

 Licensed Product against each Purchase Order in accordance with the delivery date set forth therein.

 2.2.4. Each Purchase Order shall be subject to all of the terms and conditions of this Agreement. To the extent any
terms or provisions of a Purchase Order or the written acceptance thereof by GPC Biotech conflict with, or are in addition to, the terms and provisions of this Agreement, the terms and provisions of this Agreement shall control. 
 2.3 Delivery Terms; Risk of Loss. GPC Biotech shall deliver all Licensed Product Manufactured hereunder EXW (as defined in Incoterms 2000) the
Finishing Facility. Title to all Licensed Product shall pass to Licensee at the time of delivery. 
 2.4 Regulatory Approvals. GPC
Biotech shall, and shall cause its Subcontractors to, permit any applicable Regulatory Authority to inspect the Facilities and otherwise cooperate fully with such agencies and GPC Biotech shall, and shall cause its Subcontractors to, provide
Licensee with such information and assistance as Licensee may reasonably request in order for Licensee to comply with the requirements of such Regulatory Authorities in regard to the Licensed Product. The Parties further agree that GPC Biotech
shall, and shall cause its Subcontractors to, use commercially reasonable efforts, at Licensee’s expense, to cooperate in any registration process in the Licensee Territory undertaken by Licensee in accordance with the License Agreement. On or
prior to the date agreed to by the Parties (in consultation with the JMC) in connection with the Development of the Licensed Product, GPC Biotech shall, and shall cause its Subcontractors to, at its expense, compile and file a Drug Master File with
all Regulatory Authorities in the Major Market Countries in the Licensee Territory that accept such filings. If any Regulatory Authorities in the Licensee Territory do not allow for referencing Drug Master Files for purposes of obtaining Regulatory
Approval for the Licensed Product, GPC Biotech shall, and shall cause its Subcontractors to, provide Licensee with all information required to complete the CMC Sections of any Regulatory Documentation required to be submitted in the Major Market
Countries in the Licensee Territory as soon as reasonably practicable. 
 2.5 Change Control. GPC Biotech shall Manufacture Licensed
Product according to cGMP and the applicable Specifications. GPC Biotech shall notify Licensee of any and all changes it proposes in its Manufacturing (including API and Materials), Subcontractors, Facilities, Manufacturing Process or Specifications
relating to Licensed Product. GPC Biotech or Licensee may, at any time, request a change to the Manufacturing Process or the Specifications related to the Licensed Product. GPC Biotech and its Subcontractors agree to implement any change to the
Manufacturing Process or Specifications that is required by a Regulatory Authority or by Applicable Law in the Licensee Territory. In the event of any other request to modify the Manufacturing Process or Specifications, both Licensee and GPC Biotech
shall promptly meet to evaluate such proposed changes including the effect of such changes on the regulatory filings related to the Licensed Product and the costs associated with Manufacturing. No such change shall be made without the approval of
both Parties; provided that such approval shall not be unreasonably withheld. To the extent that any change is required by Regulatory Authorities in both the GPC Biotech Territory and the Licensee Territory, the costs associated with
implementing such change will be considered Collaboration Costs under 
  

 8 

 the License Agreement. The costs associated with implementing all other changes will be the responsibility of
(a) GPC Biotech, if GPC Biotech or its Subcontractors requested the change or the change was required by Regulatory Authorities anywhere in the GPC Biotech Territory, or (b) Licensee, if Licensee requested the change or the change was
required by Regulatory Authorities anywhere in the Licensee Territory. 
 2.6 Lot Numbers. GPC Biotech shall imprint the lot numbers
and expiration dates on Licensed Product containers, as required by cGMP, for each Licensed Product delivered. Such lot numbers and expiration dates shall be assigned to each lot by GPC Biotech based on GPC Biotech’s or its Subcontractor’s
standard operating procedures. 
 2.7 Analytical Methods Transfer. Licensee shall be responsible for primary and secondary packaging
and release testing for Licensed Products to be sold by Licensee in the Licensee Territory. In accordance with a work plan and budget to be agreed upon by Licensee and GPC Biotech, GPC Biotech shall provide Licensee with (a) validated
analytical methods and reference standards; (b) details of the packaging materials that GPC Biotech has used for its stability studies; and (c) technical support required to transfer the methods to a Third Party laboratory selected by
Licensee to perform release testing of Licensed Product provided to Licensee hereunder. The transfer of analytical methods and other related technology hereunder shall be under the supervision and direction of the JMC. Licensee shall pay GPC
Biotech’s actual out-of-pocket expenses in connection with conducting the activities described in this Section 2.7. 
 2.8
Licensed Product Failure and Rejection; Latent Defects. With each delivery of Licensed Product hereunder, GPC Biotech shall provide a Certificate of Analysis and a Certificate of Compliance, in a form agreed to by the Parties, along with all
other documentation required pursuant to the Quality Agreement. Within thirty (30) days following delivery to Licensee of such Licensed Product and all such documentation, Licensee shall have the right to give GPC Biotech notice of rejection of
any batch of Licensed Product that, in whole or part, fails to meet the applicable Specifications at the time of delivery. Failure by Licensee to give notice of rejection within the period set forth above shall be deemed acceptance by it of the
Licensed Product to which the notice of rejection would have otherwise applied. GPC Biotech retains the right of appeal to an independent laboratory as provided in Section 2.16 of this Agreement. Notwithstanding the foregoing, the requirement
for Licensee to provide notice of rejection within the period set forth above shall not apply to any defect not readily discoverable by Licensee within such thirty (30) day period. In the event of any Licensed Product with defects not readily
discoverable by Licensee within such thirty (30) day period, notwithstanding anything to the contrary contained herein, Licensee may reject such Licensed Product by delivering notice of rejection to GPC Biotech no later than the earlier of:
(a) thirty (30) days after the date of discovery of such defect or (b) expiration of the shelf life of the Licensed Product. If Licensee fails to notify GPC Biotech of such defect within such time period, Licensee shall be deemed to
have accepted such Licensed Product. Licensee shall promptly supply GPC Biotech with any evidence it has that relates to whether any Licensed Product delivered to Licensee by GPC Biotech fails to meet the applicable Specifications. 
 2.9 Inspection. Licensee shall have the right, no more than once during any Calendar Year during the Term, except for any additional “for
cause” inspections where Licensee has been informed of quality issues at any of the Facilities, to enter the Facilities upon 
  

 9 

 reasonable advance notice and during normal business hours for the purpose of inspecting the Facilities, procedures and
any relevant records relating to the Manufacture of Licensed Product (including all batch sheets and records for all Manufacturing steps); provided, however, that, with respect to any audit of a Subcontractor’s facility, Licensee agrees
to enter into a customary confidentiality agreement reasonably acceptable to such Subcontractor prior to such audit and upon such Subcontractor’s request; and provided further, that any inspection of the API Facility or Finishing Facility shall
be coordinated with any inspection planned by GPC Biotech. No such inspection shall diminish or increase GPC Biotech’s obligations hereunder, except that GPC Biotech shall, and shall cause its Subcontractors to, undertake to use commercially
reasonable efforts to correct promptly any deficiencies reasonably identified by Licensee in such inspection. In the event that any Facility used in the Manufacturing of Licensed Product hereunder is inspected by representatives of any Regulatory
Authority in connection with the Manufacture of the Licensed Product, GPC Biotech shall notify Licensee immediately by telephone and follow up in writing, upon learning of such inspection, and shall promptly supply Licensee with copies of any
reports or responses prepared by the Regulatory Authority, GPC Biotech or the applicable Subcontractor relating to such inspection. Licensee may send representatives to such Facility and Licensee may participate in any portion of such inspection
relating to the Licensed Product of which GPC Biotech receives advance notice. 
 2.10 Manufacturing Records. GPC Biotech shall, and
shall cause its Subcontractors to, maintain adequate and accurate books and records with respect to its and their activities hereunder, including Manufacturing records and lot traceability records, with respect to each Licensed Product lot delivered
hereunder. These records shall be retained until Licensee gives GPC Biotech written consent for records to be destroyed, which consent shall not be unreasonably withheld; provided, however, that in no event shall records be destroyed at any
time when such records are required to be retained by Applicable Law. Notwithstanding the foregoing, GPC Biotech shall, prior to discarding any documentation related to the Manufacture of Licensed Product, make such documentation available for
collection by Licensee at Licensee’s expense. 
 2.11 Batch Records. Upon request by Licensee, GPC Biotech shall make available
for review copies of the individual and master batch records received from Subcontractors and used for any step in the Manufacture of Licensed Product delivered hereunder. Licensee may use the information in such batch records as provided in the
License Agreement, including in regulatory submissions in order to gain or maintain regulatory approvals. 
 2.12 Deviations. GPC
Biotech agrees that it or its Subcontractor’s quality assurance function shall review the Manufacturing records for all steps and all lots of Licensed Product delivered hereunder. Upon discovery of any deviation from cGMP or from any warranty
hereunder, GPC Biotech shall promptly notify Licensee and conduct an appropriate investigation to determine the cause of such deviation and take appropriate action at its expense to avoid recurrence. GPC Biotech shall provide Licensee with the
applicable documentation of such deviations and report to Licensee on the results of the subsequent investigation and corrective actions taken to address such deviations. 
  

 10 

 2.13 Warning Letters. Each Party shall promptly notify the other Party of, and provide the other
Party with copies of, any correspondence and/or other documentation received or prepared by the Party in connection with receipt of any warning letter or other regulatory correspondence from the FDA or any other Regulatory Authority in connection
with the Manufacture of the Licensed Product; provided that GPC Biotech may redact from such communications portions thereof which it is required to keep confidential pursuant to binding agreements with Third Parties. 
 2.14 Annual Reports. GPC Biotech shall supply, on a Calendar Year basis, Licensed Product data related to applicable complaint test results, all
investigations (regarding Manufacturing) and the like, at Licensee’s expense, which Licensee reasonably requires in order to complete any filing under any applicable regulatory regime, including any annual product review report that Licensee is
required to file with any applicable Regulatory Authority. 
 2.15 Communication With Governmental Agencies. Subject to the rights and
obligations set forth in the License Agreement, each Party may communicate with any governmental agency, including but not limited to governmental agencies responsible for granting regulatory approval for the Licensed Product, regarding such
Licensed Product if, in the opinion of that Party’s counsel, such communication is necessary to comply with the terms of this Agreement or the requirements of any law, governmental order or regulation; provided, however, that, unless in
the reasonable opinion of its counsel there is a legal prohibition against doing so, such Party shall permit the other Party to accompany and take part in relevant communications with the agency, to receive copies of all such communications from the
agency and to review and provide comments on any written communication with any Regulatory Authority or other government agency prior to submitting such communication. 
 2.16 Quality Claims. 
 2.16.1. Independent Laboratory. In the event of any
disagreement between GPC Biotech and Licensee relating to Licensed Product conformance to the Specifications at the time of delivery thereof by GPC Biotech to Licensee, the Parties shall use good faith efforts to reach an amicable resolution of such
disagreement. In the event that resolution cannot be reached by the Parties within fifteen (15) Business Days, a mutually agreed upon, neutral, independent laboratory meeting the requirements of cGMP shall be brought in to resolve the
disagreement upon the request of either Party. Such laboratory shall use the test methods contained in the applicable Specifications. The cost of such laboratory shall be borne by the Party determined by the laboratory to be the non-prevailing Party
in such disagreement. The findings of such laboratory shall be binding on Licensee and GPC Biotech solely with respect to determining whether a particular batch, portion of a batch, or multiple batches of Licensed Product conform with the
Specifications. Notwithstanding anything set forth in this Agreement to the contrary, GPC Biotech expressly understands and agrees that Licensee shall have the sole and final authority to determine whether all or a portion of any batch of Licensed
Product is suitable for release and distribution. In those instances where Licensee has rejected any Licensed Product which has otherwise, according to the provisions of this Section 2.16.1, been deemed suitable for use, Licensee shall pay

  

 11 

 GPC Biotech for such Licensed Product in accordance with the terms of this Agreement. 
 2.16.2. Certain Remedies for Non-Conforming Licensed Product. In the event that any Licensed Product delivered hereunder is
determined to be not in conformance with the applicable Specifications at the time of delivery, such Licensed Product shall be returned by Licensee to GPC Biotech at GPC Biotech’s expense and GPC Biotech shall use commercially reasonable
efforts to replace such nonconforming Licensed Product within sixty (60) days of such return at no extra charge to Licensee. In the event GPC Biotech cannot replace such nonconforming Licensed Product within such sixty (60) day period, it
shall refund to Licensee the amount paid therefor. GPC Biotech shall also reimburse Licensee for freight and any other shipment expenses incurred by Licensee in connection with the disposition or return of any rejected Licensed Product.
Licensee acknowledges and agrees that in no event shall GPC Biotech have any liability of any kind for Licensed Product that fails to conform to the applicable Specifications due to acts, omissions or circumstances occurring after the delivery
thereof. 
 2.17 Second Source; Allocation of Inventory and Supply. 
 2.17.1. The Parties intend to have identified and qualified one or more second source manufacturers for the Licensed Products and
API during the term of this Agreement. Except as set forth in Section 8.5 in the event of a Supply Failure, the second source manufacturer shall be selected and qualified by GPC Biotech, with Licensee’s written approval, in accordance with
the terms of GPC Biotech’s existing agreements with its Subcontractors; provided that any such second source shall be approved by applicable Regulatory Authorities and shall comply with the provisions of Section 2.4 hereof with
respect to the completion of a Drug Master File or, if applicable, CMC Sections of any Regulatory Documentation required to be submitted in the Licensee Territory. The schedule for the qualification of the second source will be agreed upon by the
JMC promptly after the Effective Date. 
 2.17.2. In addition to the requirements of Section 2.1.2 hereof with
respect to Reserve Inventory levels, in the event of any shortage of available supply of API, Materials or Licensed Product for any reason, GPC Biotech shall, during the period of any such shortage, allocate at least [...***...] of its
available Manufacturing capacity at the Facilities to supply Licensed Product to Licensee under this Agreement. 
  

	***	Confidential Treatment Requested 

  

 12 

 ARTICLE III 
 CONSIDERATION 
 3.1 Payment Terms; Price. 
 3.1.1. Invoicing. Concurrently with or promptly following the delivery of any Licensed Product hereunder, GPC Biotech shall submit
to Licensee an invoice covering such Licensed Product. Each such invoice shall, to the extent applicable, identify Licensee’s Purchase Order number, Licensed Product and lot numbers, names and quantities, unit price and the total amount to be
remitted by Licensee. In addition, each invoice shall include documentation that, in reasonable detail, supports GPC Biotech’s calculation of Manufacturing Cost in a format to be agreed upon by the Parties. Licensee shall pay all such invoices
within forty five (45) days after receipt thereof. 
 3.1.2. Purchase Price. The purchase price to be paid by
Licensee for all Licensed Product delivered hereunder shall be an amount equal to the Supply Price for such Licensed Product. 
 3.1.3. Use of Product From Validation Batches. The Parties intend that where Licensed Product Manufactured in any validation batches produced by GPC Biotech or its Subcontractors satisfies all of the requirements set forth in Article
6 hereof, such product may be provided to Licensee under the terms of this Agreement for sale in the Licensee Territory. In this event, where the Manufacturing Costs for the Licensed Products produced in such validation batches were included in
Collaboration Costs under the License Agreement, Licensee shall be entitled to a credit applicable against the Supply Price in an amount equal to the portion of such Collaboration Costs specifically attributable to the Manufacture of such validation
batches paid by Licensee under the License Agreement. 
 3.1.4. Estimate of Future Manufacturing Costs; Audits. On or
before the date that is twelve (12) months prior to the anticipated date of commercial launch of the Licensed Products in the Licensee Territory and annually thereafter, GPC Biotech shall notify Licensee of its estimated Manufacturing Cost for
the Licensed Product that will apply for the next one-year period and provide supporting documentation for such Manufacturing Cost calculations. The JMC shall meet to review the estimated Manufacturing Costs provided hereunder and to consider any
actions that might be taken to reduce such Manufacturing Costs. GPC Biotech shall maintain reasonably detailed and complete records of its Manufacturing Costs in accordance with generally accepted accounting principles applicable in the United
States during the term of this Agreement and for a period of not less than three (3) years from the expiration date of each batch to which such records pertain or such longer period as may be required by Applicable Law. Licensee shall have the
right, no more than once during any Calendar Year during the Term, to conduct an audit of GPC Biotech’s books and records upon reasonable advance notice and during normal business 
  

 13 

 hours for the purpose of verifying Manufacturing Costs invoiced to Licensee hereunder. 
 3.2 Mode of Payment. All payments to GPC Biotech under this Agreement shall be made by deposit of Euros in the requisite amount to such bank
account as GPC Biotech may from time to time designate by notice to Licensee. 
 3.3 Taxes. The purchase price payable by Licensee for
Licensed Product in accordance with Section 3.1.2 excludes all sales, use, value added or other similar taxes or duties payable in connection with the sale of such Licensed Product; any and all of which shall be the sole responsibility of
Licensee. 
 3.4 Interest on Late Payment. If any payment due to GPC Biotech under this Agreement is overdue on any amounts invoiced
that are not subject to a good faith dispute by Licensee, then Licensee shall pay interest thereon (before and after any judgment) at an annual rate (but with interest accruing on a daily basis) of the lesser of four percent (4%) above the
prime rate as reported in The Wall Street Journal, Eastern Edition, and the maximum rate allowed by Applicable Law, such interest to run from the date upon which payment of such sum became due until payment thereof in full together with such
interest. 
 ARTICLE IV 
 INTELLECTUAL PROPERTY 
 4.1 Ownership of Specifications and Manufacturing Process. Licensee acknowledges and agrees
that, as between the Parties, the Specifications and Manufacturing Processes for the Licensed Product shall be the sole and exclusive property of GPC Biotech, subject to the licenses granted to Licensee under the License Agreement. 
 ARTICLE V 
 CONFIDENTIALITY

 5.1 Confidentiality and Non-Disclosure. Each Party acknowledges and agrees that any information furnished or otherwise made
known to it, directly or indirectly, by the other Party in connection with this Agreement shall constitute Confidential Information of the other Party for all purposes of the License Agreement, except to the extent that any such information is not
included in the Definition of Confidential Information pursuant to Section 11.1 of the License Agreement. Notwithstanding anything in the foregoing sentence to the contrary, Licensee acknowledges and agrees that Specifications and Manufacturing
Processes for the Licensed Product shall constitute the Confidential Information of GPC Biotech subject to all applicable terms and conditions set forth in the License Agreement. 
 ARTICLE VI 
 REPRESENTATIONS AND WARRANTIES 
 6.1 Representations and Warranties of GPC Biotech. GPC Biotech represents, and warrants to Licensee that: 
  

 14 

 6.1.1. It or its Subcontractors have obtained (or shall obtain prior to
Manufacturing Licensed Product), and shall remain in compliance with during the Term, all permits, licenses and other authorizations (the “Permits”) which are required by Applicable Law to the Manufacture Licensed Product as
specified by this Agreement and for qualification of the Facilities for such purposes; provided, however, GPC Biotech shall have no obligation under this Agreement to obtain Permits relating to the sale, marketing, distribution or use
of API or Licensed Product or with respect to the labeling of Licensed Product; 
 6.1.2. All Manufacturing under this
Agreement shall be conducted in accordance in all respects with cGMP, including (i) availability of adequate personnel and facilities to comply with such requirements and (ii) all other processes, methods and requirements necessary for compliance
with cGMP and all other Applicable Laws, the Manufacturing Process, the Quality Agreement and the Specifications. In addition, all Manufacturing shall be conducted in accordance with GPC Biotech’s or its
Subcontractor’s standard operating procedures; 
 6.1.3. At the time of delivery thereof to Licensee, the
Licensed Product Manufactured under this Agreement, shall be in conformance with the applicable Specifications and shall not be adulterated or misbranded within the meaning of the FFDCA or any substantially similar definition under other Applicable
Law; 
 6.1.4. It has not been debarred, nor is it subject to a pending debarment, and shall not use the services of
any Persons debarred pursuant to section 306 of the FFDCA, 21 U.S.C. § 335(a) or (b) in any capacity associated with or related to the Manufacture of the Licensed Product. GPC Biotech shall promptly inform Licensee in writing of any debarment,
or the commencement of any debarment or like proceedings against GPC Biotech, its employees, officers, agents or Subcontractors, during the Term. GPC Biotech also warrants that neither GPC Biotech nor any of its officers or employees has been
convicted of a felony under the U.S. federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product, new drug application or abbreviated new drug application and neither GPC
Biotech nor any of its officers or employees has been convicted of a felony under the U.S. federal law for conduct relating to the regulation of any product under the FFDCA; and 
 6.1.5. To GPC Biotech’s Knowledge, as of the Effective Date, GPC Biotech is in compliance in all material respects with the
terms of its agreements with Subcontractors relating to the Facilities (the “Subcontractor Agreements”). GPC Biotech covenants to Licensee and agrees that it shall use all commercially reasonable efforts not to take any action or omit to
take any action that would constitute a breach of the Subcontractor Agreements or enter into any amendment to the Subcontractor Agreements, which amendment would be reasonably likely to have a material adverse effect on the Manufacturing of the

  

 15 

 Licensed Product in the Licensee Territory or GPC Biotech’s ability to perform its obligations under
this Agreement. GPC Biotech shall provide Licensee promptly with notice of the occurrence of any such breach or any notice alleging that GPC Biotech has committed any such breach. 
 6.2 Representations and Warranties of Each Party. Each Party represents and warrants to the other Party that it has the full power and
right to enter into this Agreement and that there are no outstanding agreements, assignments, licenses, encumbrances or rights of any kind held by other parties, private or public, inconsistent with the provisions of this Agreement. 
 6.3 DISCLAIMER OF WARRANTY. EXCEPT FOR THE EXPRESS WARRANTIES SET FORTH IN SECTIONS 6.1 AND 6.2, GPC BIOTECH MAKES NO REPRESENTATIONS AND
GRANTS NO WARRANTIES, EXPRESS OR IMPLIED, EITHER IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND GPC BIOTECH SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, WHETHER WRITTEN OR ORAL, OR EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF QUALITY,
MERCHANTABILITY OR FITNESS FOR A PARTICULAR USE OR PURPOSE OR ANY WARRANTY AS TO THE VALIDITY OF ANY PATENTS OR THE NON-INFRINGEMENT OF ANY INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES. LICENSEE’S EXCLUSIVE REMEDY FOR BREACH OF WARRANTY BY GPC
BIOTECH SHALL BE DIRECT DAMAGES AND GPC BIOTECH’S OBLIGATION TO REPAIR OR REPLACE THE LICENSED PRODUCT AND RESUBMIT IT TO LICENSEE IN ACCORDANCE WITH THE PROVISIONS OF SECTION 2.8. 
 ARTICLE VII 
 INDEMNITY 
 7.1 Indemnification of GPC Biotech. Licensee agrees to indemnify, defend and hold harmless GPC Biotech, its Affiliates and their respective
directors, officers, employees and agents from and against any and all losses, damages liabilities, lawsuits, proceedings, costs and expenses arising therefrom, including without limitation, reasonable attorneys’ fees and the cost of recalls
(collectively, “Losses”) in connection with any and all suits, investigations, claims or demands of Third Parties (collectively, “Claims”) arising from or occurring as a result of (a) the breach by Licensee of
this Agreement or (b) the negligence or willful misconduct on the part of Licensee in performing its obligations under this Agreement, except for those Losses for which GPC Biotech has an obligation to indemnify Licensee pursuant to
Section 7.2 hereof, as to which Losses each Party shall indemnify the other to the extent of their respective liability; provided, however, that Licensee shall not be obligated to indemnify GPC Biotech for any Losses to the extent
that such Losses arise as a result of gross negligence or willful misconduct on the part of GPC Biotech or any of its Affiliates. 
 7.2
Indemnification of Licensee. Subject to Section 7.4, GPC Biotech agrees to indemnify, defend and hold harmless Licensee, its Affiliates and their respective directors, officers, employees and agents from and against any and all Losses in
connection with any and all Claims arising from or occurring as a result of (a) the breach by GPC Biotech or any Subcontractor of this Agreement or (b) the negligence or willful misconduct on the part of GPC 
  

 16 

 Biotech or any Subcontractor in performing its obligations under this Agreement or a Subcontract, except for those Losses
for which Licensee has an obligation to indemnify Licensee pursuant to Section 7.1 hereof, as to which Losses each Party shall indemnify the other to the extent of their respective liability; provided, however, that GPC Biotech
shall not be obligated to indemnify Licensee for any Losses to the extent that such Losses arise as a result of gross negligence or willful misconduct on the part of Licensee or any of its Affiliates, Sublicensees or Distributors. 
 7.3 Indemnification Procedures. 
 7.3.1. All indemnification claims in respect of a Party, its Affiliates or their respective directors, officers, employees and agents shall be made solely by such Party to this Agreement (the
“Indemnified Party”). The Indemnified Party shall give the indemnifying Party prompt written notice (an “Indemnification Claim Notice”) of any Losses or discovery of fact upon which such indemnified Party intends to
base a request for indemnification under Section 7.1 or 7.2, but in no event shall the indemnifying Party be liable for any Losses that result from any delay in providing such notice. Each Indemnification Claim Notice must contain a description
of the claim and the nature and amount of such Loss (to the extent that the nature and amount of such Loss is known at such time). The Indemnified Party shall furnish promptly to the indemnifying Party copies of all papers and official documents
received in respect of any Losses and Claims. 
 7.3.2. At its option, the indemnifying Party or, if GPC Biotech is the
indemnifying Party and at GPC Biotech’s option, any Subcontractor, may assume the defense of any Claim by giving written notice to the Indemnified Party within thirty (30) days after the indemnifying Party’s receipt of an
Indemnification Claim Notice, which notice shall include an express agreement to undertake the defense of such Claim in accordance with the provisions of this Article 7. The assumption of the defense of a Claim by the indemnifying Party shall not be
construed as an acknowledgment that the indemnifying Party is liable to indemnify the Indemnified Party in respect of the Claim, nor shall it constitute a waiver by the indemnifying Party of any defenses it may assert against the Indemnified
Party’s claim for indemnification. Upon assuming the defense of a Claim, the indemnifying Party may appoint as lead counsel in the defense of the Claim any legal counsel selected by the indemnifying Party. In the event the indemnifying Party
assumes the defense of a Claim, the Indemnified Party shall immediately deliver to the indemnifying Party all original notices and documents (including court papers) received by the Indemnified Party in connection with the Claim. Should the
indemnifying Party assume the defense of a Claim, except as provided in Section 7.3.1, the indemnifying Party shall not be liable to the Indemnified Party for any legal expenses subsequently incurred by such Indemnified Party in connection with
the analysis, defense or settlement of the Claim. In the event that it is ultimately determined that the indemnifying Party is not obligated to indemnify, defend or hold harmless the Indemnified Party from and against the Claim, the Indemnified
Party shall reimburse the indemnifying 
  

 17 

 Party for any and all costs and expenses (including attorneys’ fees and costs of suit) incurred by
the indemnifying Party in its defense of the Third Party Claim. 
 7.3.3. Without limiting Section 7.3.2 above,
any Indemnified Party shall be entitled to participate in, but not control, the defense of such Claim and to employ counsel of its choice for such purpose; provided, however, that such employment shall be at the Indemnified
Party’s own expense unless (i) the employment thereof has been specifically authorized by the indemnifying Party in writing, (ii) the indemnifying Party has failed to assume the defense and employ counsel in accordance with
Section 7.3.2 (in which case the Indemnified Party shall control the defense) or (c) the interests of the Indemnified Party and the indemnifying Party (or, if applicable, an indemnifying Subcontractor) with respect to such Claim are
sufficiently adverse to prohibit the representation by the same counsel of both parties under applicable law, ethical rules or equitable principles. 
 7.3.4. With respect to any Loss relating solely to the payment of money damages in connection with a Claim that shall not result in the Indemnified Party’s becoming subject to injunctive or other relief or
otherwise adversely affecting the business of the Indemnified Party in any manner, and as to which the indemnifying Party shall have acknowledged in writing the obligation to indemnify the Indemnified Party hereunder, the indemnifying Party shall
have the sole right to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss, on such terms as the indemnifying Party, in its sole discretion, shall deem appropriate; provided that such disposition
includes as an unconditional term thereof the giving by the claimant or plaintiff to the Indemnified Party of a release of all liability in respect thereof. With respect to all other Losses in connection with any Claim, where the indemnifying Party
has assumed the defense of the Claim in accordance with Section 7.3.2, the indemnifying Party shall have authority to consent to the entry of any judgment, enter into any settlement or otherwise dispose of such Loss provided it obtains
the prior written consent of the Indemnified Party (which consent shall not be unreasonably withheld or delayed). Regardless of whether the indemnifying Party chooses to defend or prosecute any Claim, no Indemnified Party shall admit any liability
with respect to or settle, compromise or discharge, any Third Party Claim without the prior written consent of the indemnifying Party, such consent not to be unreasonably withheld or delayed. 
 7.3.5. If the indemnifying Party chooses to defend or prosecute any Claim, the Indemnified Party shall, and shall cause each
Indemnified Party to, cooperate in the defense or prosecution thereof and shall furnish such records, information and testimony, provide such witnesses and attend such conferences, discovery proceedings, hearings, trials and appeals as may be
reasonably requested in connection therewith. Such cooperation shall include access during normal business hours afforded to indemnifying Party to, and reasonable retention by the Indemnified Party of, records and information that are reasonably
relevant to such Claim, and making indemnified Parties and other 
  

 18 

 employees and agents available on a mutually convenient basis to provide additional information and
explanation of any material provided hereunder, and the indemnifying Party shall reimburse the Indemnified Party for all its reasonable out-of-pocket expenses in connection therewith. 
 7.3.6. Except as provided above, the costs and expenses, including fees and disbursements of counsel, incurred by the Indemnified
Party in connection with any Claim shall be reimbursed on a Calendar Quarter basis by the indemnifying Party, without prejudice to the indemnifying Party’s right to contest the Indemnified Party’s right to indemnification and subject to
refund in the event the indemnifying Party is ultimately held not to be obligated to indemnify the Indemnified Party. 
 7.4
Limitations. 
 7.4.1. EXCEPT IN CIRCUMSTANCES OF GROSS NEGLIGENCE OR INTENTIONAL MISCONDUCT BY A PARTY OR ITS
AFFILIATES (OR WITH RESPECT TO LICENSEE, ITS SUBLICENSEES OR DISTRIBUTORS), OR WITH RESPECT TO CLAIMS UNDER SECTION 7.1 OR 7.2, NO PARTY OR ANY OF THEIR RESPECTIVE AFFILIATES SHALL BE LIABLE FOR SPECIAL, INDIRECT, INCIDENTAL, PUNITIVE OR
CONSEQUENTIAL DAMAGES, INCLUDING LOST PROFITS, WHETHER IN CONTRACT, WARRANTY, NEGLIGENCE, TORT, STRICT LIABILITY OR OTHERWISE, ARISING OUT OF ANY BREACH OF OR FAILURE TO PERFORM ANY OF THE PROVISIONS OF THIS AGREEMENT. 
 7.4.2. NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, THE PARTIES AGREE THAT THE AGGREGATE MONETARY LIABILITY OF GPC BIOTECH FOR
ANY BREACH OF THE TERMS OF THIS AGREEMENT BY A SUBCONTRACTOR SHALL BE SUBJECT TO ANY LIMITATIONS ON LIABILITY SPECIFIED IN GPC BIOTECH’S AGREEMENT WITH SUCH SUBCONTRACTOR; PROVIDED, HOWEVER, THAT NOTHING IN THIS SECTION 7.4.2 SHALL
OPERATE TO LIMIT GPC BIOTECH’S LIABILITY OR LICENSEE’S REMEDIES SPECIFIED IN THE LICENSE AGREEMENT OR ANY NON-MONETARY REMEDIES EXPRESSLY PROVIDED IN THIS AGREEMENT. 
 ARTICLE VIII 
 TERM AND TERMINATION 
 8.1 Term. Unless earlier terminated as provided herein, the term of this Agreement (the “Term”) shall commence on the Effective
Date and shall expire on a country-by-country basis on the date of expiration or termination of the License Agreement for any reason with respect to such country or countries. 
  

 19 

 8.2 Termination of this Agreement for Material Breach. In the event that either Party (the
“Breaching Party”) shall be in material default in the performance of any of its material obligations under this Agreement, in addition to any other right and remedy the other Party (the “Complaining Party”) may
have, the Complaining Party may terminate this Agreement, in its entirety by sixty (60) days’ prior written notice (the “Notice Period”) to the Breaching Party, specifying the breach and its claim of right to terminate;
provided always that the termination shall not become effective at the end of the Notice Period if the Breaching Party cures the breach complained about during the Notice Period (or, if such default cannot be cured within such sixty (60)-day
period, if the Breaching Party commences actions to cure such default within the Notice Period and thereafter diligently continues such actions; provided further that such default is cured within one hundred eighty (180) days after the
receipt of such notice), except in the case of a payment default (with respect to amounts invoiced by GPC Biotech that are not subject to a good faith dispute by Licensee), as to which the Breaching Party shall have only a ten (10)-day cure period.

 8.3 Termination by Either Party. Either Party shall have the right to terminate this Agreement by written notice to the other Party
upon the occurrence of any of the following: (a) the other Party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for
the benefit of creditors, or becomes subject to involuntary proceedings under any bankruptcy or insolvency law (which proceedings remain undismissed for sixty (60) days) or (b) a force majeure event pursuant to Section 9.6.

 8.4 Accrued Rights; Surviving Obligations. 
 8.4.1. Accrued Rights. Termination or expiration of this Agreement for any reason shall be without prejudice to any rights that
shall have accrued to the benefit of a Party prior to such termination or expiration. Such termination or expiration shall not relieve a Party from obligations that are expressly indicated to survive the termination or expiration of this Agreement.

 8.4.2. Materials. Upon termination of this Agreement for any reason except termination by Licensee pursuant to
Section 8.2, Licensee promptly shall reimburse GPC Biotech for the actual costs of all API, Materials and work in process in the possession of GPC Biotech or its Subcontractors, or which GPC Biotech or its Subcontractors have committed to
purchase (unless cancelable); provided that the amounts of such API, Materials and work in process shall not exceed the quantities necessary to Manufacture the amount of Licensed Product specified in the binding portion of the most recently
submitted Forecast (as provided in Section 2.2.2), unless the Parties mutually agree that inventory levels of API and Materials may exceed the requirements for such periods; provided further that Licensee shall only be liable for any
such inventory of API, Materials and work in process including excess inventory mutually agreed by the Parties, that is not otherwise usable by GPC Biotech in the ordinary course of business. 
  

 20 

 8.4.3. Survival. Without limiting the foregoing, Sections 2.8, 2.10, 2.16,
3.2, 3.3, 3.4, 6.3, 9.1, 9.2, 9.3, 9.5, 9.7, 9.8, 9.9, 9.10, 9.11, 9.12, 9.13, 9.15, 9.16, this Section 8.4, and Articles IV, V and VII of this Agreement shall survive the termination or expiration of this Agreement for any reason.

 8.5 Failure of Supply. In the event of a Supply Failure (as defined below), Licensee shall have the right to identify, establish
and maintain a Third Party manufacturer as a second source for the supply of Licensed Product or API, as applicable (a “Second Source”). No later than ten (10) Business Days after a Supply Failure, the JMC shall establish a schedule
and budget for activities and responsibilities of the parties, including technology transfer, required to establish the Second Source. Promptly after the selection of a Second Source for the Licensed Product by Licensee and such Second Source enters
into a written agreement with GPC Biotech, GPC Biotech shall commence transfer to such Second Source of technology relating to the Manufacturing Process for the Licensed Product which transfer shall be completed as soon as practicable thereafter,
subject to the applicable terms of such agreement. Such agreement shall include (a) licenses under Intellectual Property Rights Controlled by GPC Biotech to the extent required to enable the Second Source to Manufacture the Licensed Products
for Licensee and (b) adequate protection for the trade secrets and other confidential information of GPC Biotech relating to transferred technology. GPC Biotech shall bear the expenses (including any payments to Third Parties) associated with
the activities under this Section 8.5, unless the cause of the Supply Failure is a Force Majeure event (as described in Section 9.6) in which case such costs and expenses shall be deemed “Collaboration Costs” subject to the terms
of the License Agreement. For purposes of this Section 8.5, a “Supply Failure” shall be deemed to occur if, at any time during the term of this Agreement, GPC Biotech fails to deliver to Licensee an amount of Licensed Product
conforming to the requirements of Article 6 hereof of less than (i) [...***...] of the quantities specified in Purchase Orders over a period of [...***...]; or (ii) [...***...] of the quantities specified in Purchase
Orders over a period of [...***...], where in each case such quantities were properly forecast and ordered by Licensee in accordance with this Section 2. In addition, if either Party becomes aware of any conditions or
circumstances affecting the supply of Licensed Products or the Facilities that could reasonably be expected to lead to a Supply Failure, such Party will inform the other Party thereof. In such event, Licensee may then begin the process of
identifying and contacting potential Second Sources and Licensee shall work with the JMC in establishing a contingency plan for the technology transfer activities specified herein. 
 ARTICLE IX 
 MISCELLANEOUS 
 9.1 Notices. 
 9.1.1. Notice Requirements. Any notice, request, demand, waiver, consent, approval or other communication permitted or required under this Agreement shall be in writing, shall refer specifically to this Agreement and shall be deemed
given only if delivered by hand or sent by facsimile transmission (with transmission confirmed) or by internationally recognized overnight delivery service that maintains records of delivery, addressed to the 
  

	***	Confidential Treatment Requested 

  

 21 

 Parties at their respective addresses specified in Section 9.1.2 or to such other address as the
Party to whom notice is to be given may have provided to the other Party in accordance with this Section 9.1. Such Notice shall be deemed to have been given as of the date delivered by hand or transmitted by facsimile (with transmission
confirmed) or on the second business day (at the place of delivery) after deposit with an internationally recognized overnight delivery service. Any notice delivered by facsimile shall be confirmed by a hard copy delivered as soon as practicable
thereafter. This Section 9.1 is not intended to govern the day-to-day business communications necessary between the Parties in performing their obligations under the terms of this Agreement. 
 9.1.2. Address for Notice 
 If to Licensee, to: 
 Pharmion GmbH 
 Aeschenvorstadt 71, 
 4051 Basel, 
 Switzerland 
 Attention: Director 

Facsimile: +41 61 305 9899 
 with a copy
to: 
 Pharmion Corporation 
 2525
28th Street 
 Boulder, Colorado 80301 
 Attention: VP and General Counsel 
 Facsimile: 720 564 9191 
 If to GPC Biotech,
to: 
 GPC Biotech AG 
 Fraunhoferstrasse 20 
 82152 Martinsried/Munich, Germany 
 Attention: Chief Executive Officer 
 Facsimile: +49 89 85 65 2610 
 with a copy to: 
 GPC Biotech Inc. 
 101 College Road East 
 Princeton, NJ 08540, U.S.A. 
 Attention:
General Counsel 
 Facsimile: +1 609 524 1050 
  

 22 

 9.2 Governing Law, Jurisdiction, Venue and Service. 
 9.2.1. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation of this Agreement to the substantive law of another jurisdiction. The Parties agree to exclude the application to this Agreement of
the United Nations Convention on Contracts for the International Sale of Goods. 
 9.2.2. Jurisdiction. Subject to
Sections 9.3 and 9.11, the Parties hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the courts of the State of New York and the United States District Court for the Southern District of New York for any
action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement, and agree not to commence any action, suit or proceeding (other than appeals therefrom) related thereto except in such courts. The Parties
irrevocably and unconditionally waive their right to a jury trial. 
 9.2.3. Venue. The Parties further hereby
irrevocably and unconditionally waive any objection to the laying of venue of any action, suit or proceeding (other than appeals therefrom) arising out of or relating to this Agreement in the courts of the State of New York or in the United States
District Court for the Southern District of New York, and hereby further irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such action, suit or proceeding brought in any such court has been brought in
an inconvenient forum. 
 9.2.4. Service. Each Party further agrees that service of any process, summons, notice or
document by registered mail to its address set forth in Section 9.1.2 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such court. 
 9.3 Waiver and Non-Exclusion of Remedies. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the
benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party hereto of any right hereunder or of the failure to
perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by said other Party whether of a similar nature or otherwise. 
 9.4 Assignment. Without the prior written consent of the other Party hereto, neither Party shall sell, transfer, assign, delegate, pledge or
otherwise dispose of, whether voluntarily, involuntarily, by operation of law or otherwise, this Agreement or any of its rights or duties hereunder; provided, however, that (a) GPC Biotech may, without such consent, delegate its
obligations hereunder in accordance with Section 2.1.1, (b) either Party may, without such consent, assign this Agreement and its rights and obligations hereunder in connection with any assignment of the License Agreement as permitted
under Section 15.4 of the License Agreement; 
  

 23 

 provided that in the case of such assignment to an Affiliate, such assigning Party shall remain responsible for
the performance by such Affiliate of the rights and obligations hereunder. Any attempted assignment or delegation in violation of the preceding sentence shall be void and of no effect. All validly assigned and delegated rights and obligations of the
Parties hereunder shall be binding upon and inure to the benefit of and be enforceable by and against the successors and permitted assigns of GPC Biotech or Licensee, as the case may be. In the event either Party seeks and obtains the other
Party’s consent to assign or delegate its rights or obligations to another Party, the assignee or transferee shall assume all obligations of its assignor or transferor under this Agreement. 
 9.5 Severability. If any provision of this Agreement is held to be illegal, invalid or unenforceable under any present or future law, and if the
rights or obligations of either Party under this Agreement shall not be materially and adversely affected thereby, (a) such provision shall be fully severable, (b) this Agreement shall be construed and enforced as if such illegal, invalid
or unenforceable provision had never comprised a part hereof, (c) the remaining provisions of this Agreement shall remain in full force and effect and shall not be affected by the illegal, invalid or unenforceable provision or by its severance
herefrom and (d) in lieu of such illegal, invalid or unenforceable provision, there shall be added automatically as a part of this Agreement a legal, valid and enforceable provision as similar in terms to such illegal, invalid or unenforceable
provision as may be possible and reasonably acceptable to the Parties. To the fullest extent permitted by applicable law, each Party hereby waives any provision of law that would render any provision hereof illegal, invalid or unenforceable in any
respect. 
 9.6 Force Majeure. Notwithstanding anything to the contrary contained herein, neither Party shall be deemed to be in
breach hereof or be liable for non-performance, defective or late performance of any of its obligations under this Agreement (other than obligations to pay money) to the extent and for such periods of time as such non-performance, defective or late
performance is due to reasons of strike, riots, war, act of God, invasion, fire, explosion, floods, delay of carrier, shortage in the supply of Materials, acts of government or governmental agencies or instrumentalities (other than such acts that
arise from or relate to violations of Applicable Law by the affected Party) and any other contingencies beyond the Parties’ or any Subcontractor’s reasonable control. The Party affected shall give written notice to the other Party of any
material delay due to such causes. In the event a force majeure event prevents a Party’s performance under this Agreement for one hundred eighty (180) consecutive days, the other Party may (in addition to all other rights of such Party
under this Agreement, including Section 8.5) terminate this Agreement upon thirty (30) days prior written notice to the other Party, but such termination shall not be deemed a breach by the Party affected by the force majeure condition.

 9.7 No Benefit to Other Persons. The representations, warranties, covenants and agreements set forth in this Agreement are for the
sole benefit of the Parties hereto and their successors and permitted assigns, and they shall not be construed as conferring any rights on any other Persons. 
 9.8 Export Control. This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States or other countries that may be imposed on related to the
Parties from time to time. Each Party agrees that 
  

 24 

 it shall not export, directly or indirectly, any technical information acquired from the other Party under this Agreement
or any products using such technical information to a location or in a manner that at the time of export requires an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency or
other governmental entity in accordance with Applicable Law. 
 9.9 Relationship of the Parties. It is expressly agreed that GPC
Biotech, on the one hand, and Licensee, on the other hand, shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither GPC Biotech, on the one hand, nor
Licensee, on the other hand, shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other, without the prior written consent of the other Party to do so, such
consent not to be unreasonably withheld or delayed. All persons employed by a Party shall be employees of such Party and not of the other Party and all costs and obligations incurred by reason of any such employment shall be for the account and
expense of such Party. 
 9.10 References. Unless otherwise specified, (a) references in this Agreement to any Article or Section
shall mean references to such Article or Section of this Agreement, (b) references in any section to any clause are references to such clause of such section and (c) references to any agreement, instrument or other document in this
Agreement refer to such agreement, instrument or other document as originally executed or, if subsequently varied, replaced or supplemented from time to time, as so varied, replaced or supplemented and in effect at the relevant time of reference
thereto. 
 9.11 Dispute Resolution. 
 9.11.1. General. Except with respect to Section 2.16, if a dispute arises between the Parties in connection with or relating to this Agreement or any document or instrument delivered in connection herewith
(a “Dispute”), then either Party shall have the right to refer such dispute to the Chief Executive Officer of GPC Biotech and the Chief Executive Officer of Licensee who shall confer on the resolution of the issue. Any final
decision mutually agreed to by such representatives shall be conclusive and binding on the Parties. If such officers are not able to agree on the resolution of an issue within twenty (20) Business Days after such issue was first referred to
them, either Party may, by written notice to the other Party, elect to initiate arbitration pursuant to Section 9.11.2 for purposes of having the matter settled. 
 9.11.2. Arbitration. Any arbitration under this Agreement shall take place at a location to be agreed by the Parties;
provided, however, that in the event that the Parties are unable to agree on a location for an arbitration under this Agreement within five (5) days of the demand therefor, such arbitration shall be held in New York, New York. Any
arbitration under this Agreement shall be administered by the American Arbitration Association under its Commercial Arbitration Rules then in effect (the “Arbitration Rules”). The Parties shall appoint an arbitrator by mutual
agreement. If the Parties cannot agree on the appointment of an arbitrator within thirty (30) days of the demand for arbitration, 
  

 25 

 an arbitrator shall be appointed in accordance with the Arbitration Rules. The arbitrator shall have the
authority to grant any equitable and legal remedies that would be available in any judicial proceeding instituted to resolve the Dispute submitted to such arbitration in accordance with this Agreement; provided, however, that the
arbitrator shall not have the power to alter, amend or otherwise affect the terms or the provisions of this Agreement. Judgment upon any award rendered pursuant to this Section may be entered by any court having jurisdiction over the Parties’
other assets. The arbitrator shall have no authority to award punitive or any other type of damages not measured by a Party’s compensatory damages. Each Party shall bear its own costs and expenses and attorneys’ fees and an equal share of
the arbitrator’s fees and any administrative fees of arbitration, unless the arbitrator shall otherwise allocate such costs, expenses and fees between the Parties. The Parties agree that all arbitration awards shall be final and binding on the
Parties and their Affiliates. The Parties hereby waive the right to contest the award in any court or other forum. Except to the extent necessary to confirm or enforce an award or as may be required by law, neither a Party nor an arbitrator may
disclose the existence, content or results of an arbitration without the prior written consent of both Parties. 
 9.11.3.
Interim Relief. Notwithstanding anything herein to the contrary, nothing in this Section shall preclude either Party from seeking interim or provisional relief, including a temporary restraining order, preliminary injunction or other interim
equitable relief concerning a dispute, if necessary to protect the interests of such Party. This Section shall be specifically enforceable. 
 9.12 Entire Agreement. This Agreement sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof and all prior agreements, understandings, promises and
representations, whether written or oral, with respect thereto are superseded hereby. Notwithstanding the foregoing, in event of any conflict between the terms of this Agreement and the terms of the License Agreement, the terms of the License
Agreement shall control and take precedence. Each Party confirms that it is not relying on any representations or warranties of the other Party except as specifically set forth herein. No amendment, modification, release or discharge shall be
binding upon the Parties unless in writing and duly executed by authorized representatives of both Parties. 
 9.13 English Language.
This Agreement shall be written and executed in, and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version thereof, and in
the event of any conflict in interpretation between the English version and such translation, the English version shall control. 
 9.14
Counterparts. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. This Agreement may be executed by facsimile
signatures and such signatures shall be deemed to bind each Party hereto as if they were original signature. 
  

 26 

 9.15 Further Assurance. Each Party shall duly execute and deliver, or cause to be duly executed
and delivered, such further instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents and instruments, as may be necessary or as the other Party may reasonably request in
connection with this Agreement or to carry out more effectively the provisions and purposes hereof, or to better assure and confirm unto such other Party its rights and remedies under this Agreement. 
 9.16 Construction. Except where the context otherwise requires, wherever used, the singular shall include the plural, the plural the singular, the
use of any gender shall be applicable to all genders and the word “or” is used in the inclusive sense (and/or). The captions of this Agreement are for convenience of reference only and in no way define, describe, extend or limit the scope
or intent of this Agreement or the intent of any provision contained in this Agreement. The term “including” as used herein shall mean including, without limiting the generality of any description preceding such term. The language of this
Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied against either Party hereto. 
 [SIGNATURE PAGE FOLLOWS.] 
  

 27 

 THIS AGREEMENT IS EXECUTED by the authorized representatives of the Parties as of the
date first written above. 
  

							
	GPC BIOTECH AG	  	PHARMION GMBH
				
	Signature:	 	 /s/ Elmar Maier, PhD
	  	Signature:	 	 /s/ Patrick J. Mahaffy

	Name:	 	Elmar Maier, PhD	  	Name:	 	Patrick J. Mahaffy
	Title:	 	SVP Business Development	  	Title:	 	Director
				
	Signature:	 	 /s/ Bernd R. Seizinger, M.D., PhD
	  	Signature:	 	 /s/ Erle T. Mast

	Name:	 	Bernd R. Seizinger, M.D., PhD	  	Name:	 	Erle T. Mast
	Title:	 	CEO	  	Title:	 	Director

  

 28ASSET PURCHASE AGREEMENT

 Exhibit 4.16 
  

			
	ASSET PURCHASE AGREEMENT	  	VERTRAG ÜBER DEN KAUF DER ASSETS
		
	between	  	zwischen
		
	 1.      Blitz 05-001 GmbH (in the future: ”GPC Biotech Forschungsgesellschaft mbH”), with its seat in
Munich, registered with the commercial register of the local court Munich (AG München) under HRB 156071, represented by its Managing Director, Dr. Elmar Maier, having the power to represent the Company solely,
	  	 1.      Blitz 05-001 GmbH (künftig: ,,GPC Biotech Forschungsgesellschaft mbH”) mit Sitz in
München, eingetragen im Handelsregister des Amtsgerichts München unter HRB 156071, vertreten durch ihren alleinvertretungsberechtigten Geschäftsführer Dr. Elmar Maier

		
	- hereinafter referred to as ,,Purchaser” -,	  	- im folgenden als ,,Käufer” bezeichnet -
		
	and	  	und
		
	 2.      Rechtsanwalt Dr. Joseph Füchsl, Königinstr. 26, 80539 Munich as Insolvency Receiver
(“Insolvency Receiver”) of Axxima Pharmaceuticals AG (“Axxima”) with its seat in Max-Lebsche-Platz 32 in 81377 München, registered with the commercial register of the local court of Munich under HRB 119339
(“Company”), appointed by the ruling of the local court of Munich, Insolvency Court, as of March 1, 2005 (Docket No. 1502 IN 3692/04)
	  	 2.      Rechtsanwalt Dr. Joseph Füchsl, Königinstr. 26, 80539 München, als Insolvenzverwalter der
Axxima Pharmaceuticals AG (,,Axxima”), mit Sitz in Max- Lebsche-Platz 32 in 81377 München, eingetragen im Handelsregister des Amtsgerichts München unter HRB 119339 (,,Gesellschaft”), bestellt durch Beschluss des Amtsgerichts
München, Insolvenzgericht, vom 1. März 2005 (Geschäftsnr. 1502 IN 3694/04)

		
	- hereinafter referred to as ,,Seller” -,	  	- im folgenden ,,Verkäufer” -
		
	WITNESSETH:	  	HIERMIT WIRD FOLGENDES
		  	VEREINBART:
		
	Preamble	  	Vorbemerkungen
		
	 WHEREAS, the Company is in the business of biotechnological and chemical developments regarding the research and
 commercialisation of products in the fields of infec-
	  	Die Gesellschaft ist im Bereich biotechnologischer und chemischer Entwicklungen hinsichtlich der Forschung und Vermarktung von Produkten in den Bereichen Infektionen,

			
	tions, inflammations and cancer. Emphasis of the research activities is the search for specific kinase inhibitors for the aforementioned indications;	  	Entzündungen und Krebs tätig. Schwerpunkt der Forschungsaktivitäten ist die Suche nach spezifischen Kinase Inhibitoren für die vorgenannten Indikationen.
		
	WHEREAS, on December 27, 2004 the Company filed for the initiation of insolvency proceedings over its estate. The proceed- ings commenced as of March 1, 2005 at 9:00 a.m. A copy of the
ruling to open the proceedings is attached as Exhibit A; and	  	Die Gesellschaft hat am 27. Dezember 2004 die Eröffnung des Insolvenzverfahrens über ihr Vermögen beantragt. Das Verfahren ist am 1. März 2005 um 9:00 Uhr eröffnet
worden. Eine Kopie des Beschlusses über die Verfahrenseröffnung ist als Anlage A beigefügt.
		
	WHEREAS, Purchaser wishes to purchase and acquire from Seller, and Seller wishes to sell, assign and transfer to Purchaser, assets and properties, all for the purchase price and upon the terms
and subject to the conditions hereinafter set forth.	  	Der Käufer möchte vom Verkäufer Assets kaufen und erwerben und der Verkäufer möchte dieselben an den Käufer verkaufen, abtreten und übereignen, und zwar alle
für den Kaufpreis und zu den Bedingungen und vorbehaltlich der Konditionen, die in diesem Vertrag nachstehend festgelegt werden.
		
	NOW, THEREFORE, the parties hereto agree as follows:	  	Dies vorausgeschickt, vereinbaren die Parteien was folgt:
		
	 Sec. 1
	  	 §1

	 SALE AND PURCHASE OF THE ASSETS
	  	 KAUF UND VERKAUF DER ASSETS

		
	 1.      Subject to and upon the terms set forth in this Agreement, the Seller hereby sells, transfers and
assigns to the Purchaser those assets and rights of every nature, tangible and intangible, whether now existing or hereafter acquired, and as specified under this section 1 (the “Assets”). The right of use and exploitation of non
transferable assets shall be granted to the Buyer exclusively, transferable and unrestricted in regard to time (“auf Dauer”), territory and scope of use and exploitation, including but not limited to the right to adapt and transform as
well as to take any appropriate action to protect or register the Assets in its own name
	  	 1.      Gemäß den in diesem Vertrag festgelegten Bestimmungen verkauft und überträgt (durch
Übereignung bzw. Abtretung) der Verkäufer hiermit dem Käufer diejenigen Gegenstände und ( Rechte aller Art, gleich ob körperlich oder unkörperlich, und gleich ob dieselben gegenwärtig bereits existieren oder erst
noch erworben werden, die jeweils in diesem § 1 näher bezeichnet sind (die ,,Assets”). An allen nicht übertragbaren Assets werden auf Dauer ausschließliche, räumlich und inhaltlich uneingeschränkte und
übertragbare Nutzungs- und Verwertungsrechte, einschließlich des Rechts zur Bearbeitung und Schutzrechtsanmeldung im eigenen Namen, für alle jetzt

  

 –2/2– 

			
	 for all presently known types of use. Seller hereby waives all of his other rights as author or originator or holder of other intellectual or industrial property
rights, including but not limited to the right of recognition of authorship, the right of access to the work and the right to prohibit distortions of the work.
	  	 bekannten Nutzungsarten eingeräumt. Der Verkäufer verzichtet hiermit auf alle sonstigen ihm etwa als Urheber oder sonstigern Schutzrechtsinhaber
zustehenden Rechte, insbesondere auf die Rechte auf Namensnennung und auf Zugänglichmachung des Werkes sowie auf das Recht, Entstellungen zu untersagen.

		
	 2.      Assets shall include all items in the following categories to the extent that they are not expressly
excluded:
	  	 2.      Zu den Assets gehören alle Gegenstände der folgenden Kategorien, soweit nicht
ausdrücklich ausgeschlossen:

		
	 a.      subject to sentence 2, all intellectual property, including, but not limited to, the assets as listed in
Exhibit 1.2(1) hereto, including all patents, patent applications, utility models, utility model applications, all rights to the inventions underlying these patents (except the non-transferable personal rights of the inventors relating to the
invention), all trademarks and trademark applications, other registered and unregistered property rights, trade secrets, and confidential or proprietary information owned or licensed by the Seller including, but not limited to, rights to sue for and
remedies against past, present and future infringements thereof, and rights of priority and protection of interests therein under the laws of any jurisdiction worldwide. However, the intellectual property rights listed in Exhibit
1.2(2)
	  	 a.      Vorbehaltlich Satz 2, das gesamte geistige Eigentum, insbesondere die in Anlage 1.2(1)
aufgeführten Assets, einschließlich aller Patente, Patentanmeldungen, Gebrauchsmuste, Gebrauchsmusteranmeldungen, zu Grunde liegenden Erfindungen (ausgenommen die Erfinderpersönlichkeitsrechte), aller Warenzeichen und
Warenzeichenanmeldungen, eingetragener und nicht eingetragener sonstiger Schutzrechte, Betriebsgeheimnisse sowie vertraglich oder gesetzlich geschützter Informationen, die der Gesellschaft gehören oder für die sie über eine
Lizenz verfügt, einschließlich Klagerechte und Rechtsbehelfe wegen vergangener, gegenwärtiger und künftiger Verstöße gegen dieselben sowie diesbezügliche Vorrechte und Schutz der diesbezüglichen Rechte
weltweit. Nicht zu den Assets gehören jedoch die in

  

 –3/3– 

			
	 are excluded from the Assets.
	  	 Anlage 1.2(2) aufgeführten Gegenstände des geistigen Eigentums.

		
	 b.      all know-how including, but not limited to, all proprietary information, techniques and data directly
relating to the Assets, including, but not limited to, discoveries, formulae, materials, practices, methods, knowledge, know-how, processes, experience, test data (including pharmacological, toxicological and clinical information and test data),
analytical and quality control data, marketing, pricing, distribution, cost and sales data or
descriptions;
	  	 b.      das gesamte Know-how, einschließlich aller gesetzlich geschützten Informationen, Techniken
und Daten, das sich direkt auf die Assets bezieht, einschließlich, jedoch nicht beschränkt auf Entdeckungen, Formeln, Materialien, Praktiken, Methoden, Kenntnisse, Know-how, Verfahren, Erfahrungen, Testdaten (einschließlich
pharmakologischer, toxikologischer und klinischer Informationen und Testdaten), analytischer Daten und Qualitätssicherungsdaten, Marketing-, Preisgestaltungs-, Vertriebs-, Kosten- und Verkaufsdaten oder - beschreibungen;

		
	 c.      all tangible embodiments of and all data containing (i) any intellectual property as described
above under lit a., and/or (ii) any know-how as described above under lit b.; all books, records, manuals and other materials (in any form or medium), including, without limitation all files and documentation of the Seller, price lists,
correspondence, mailing lists, lists of customers, distribution lists, photographs, production data, sales and promotional materials and records, purchasing materials and records, personnel records, manufacturing and quality control records and
procedures, blueprints, re-search and development files, records, data and laboratory books, media and materials, accounting records, and litigation files.
	  	 c.      sämtliche Verkörperungen von, sowie sämtliche Daten in Bezug auf: (i) geistiges Eigentum
wie vorstehend unter lit. a. beschrieben und/oder (ii) Know-how wie vorstehend unter lit. b. beschrieben, insbesondere alle Bücher, Aufzeichnungen, Handbücher und sonstige Unterlagen (in jeder Form bzw. auf jedem Medium),
einschließlich sämtlicher Aufzeichnungen und Unterlagen, die vom Verkäufer geführt werden, Preislisten, Korrespondenz, Mailinglisten, Kundenlisten, Vertriebslisten, Fotografien, Produktionsdaten, Vertriebs- und Werbematerialien
und -aufzeichnungen, Einkaufsmaterialien und -aufzeichnungen, Personalaufzeichnungen, Fertigungs-

  

 –4/4– 

			
		  	 und Qualitätssicherungsaufzeichnungen und
-verfahren, Pläne, Forschungs- und Entwicklungsakten, -aufzeichnungen, -daten und Laborbücher,
Medienmaterialien, Buchführungsunterlagen und Akten über Rechtsstreitigkeiten.

		
	 3.      Assets shall include all those items, which are (i) not Assets as defined under para. 2 above, and
which (ii) are set out below:
	  	 3.      Zu den Assets gehören auch solche Gegenstände, die (i) nicht bereits in Abs. 2 aufgeführt
sind, und die (ii) im Folgenden aufgeführt sind:

		
	 a.      all inventories, including warehoused stock, spare parts, replacement and component parts, raw
materials, intermediates and office and other stocks, including inventories previously purchased and in transit;
	  	 a.      das gesamte Inventar, einschließlich Warenlager, Ersatzteile, Austausch- und Einzelteile,
Rohstoffe, Zwischenprodukte sowie Büromaterial und sonstige Bestände, einschließlich zuvor erworbenes und im Transport befindliches Inventar;

		
	 b.      all machinery, equipment, furniture and fixtures;
	  	 b.      sämtliche Gerätschaften, Ausrüstungsgegenstände und Möbel sowie
Einrichtungsgegenstände;

		
	 c.      all contracts listed in Exhibit 1.3; and
	  	 c.      sämtliche in Anlage 1.3 aufgelisteten Verträge; und

		
	 d.      all transferable governmental authorizations and permits relating to Assets sold, or employees taken
over, under this Agreement.
	  	 d.      alle übertragbaren behördlichen Genehmigungen und Erlaubnisse, die sich auf nach diesem
Vertrag verkaufte Assets bzw. übergegangene Arbeitnehmer beziehen.

		
	 4.      Except for liabilities, contingent liabilities and obligations expressly set out in this Agreement and
the exhibits thereto, the Purchaser does not assume any liabilities, contingent liabilities or obligations of the Seller.
	  	 4.      Der Käufer übernimmt außer den in diesem Vertrag und dessen Anlagen ausdrücklich
bezeichneten Verbindlichkeiten und Eventualverbindlichkeiten sowie Verpflichtungen keine Verbindlichkeiten, Eventualverbindlichkeiten oder Verpflichtungen des Verkäufers.

  

 –5/5– 

			
	 5.a.   To the extent that the Assets set out under paragraphs 2, 3a and 3b are tangible assets, the assets are hereby handed
over, by way of the Seller keeping them only on behalf of the Purchaser from now on. The Seller shall grant access to the data stored in EDP media or otherwise to the Purchaser only.
	  	 5.a.   Soweit es sich bei den unter Abs. 2, 3a. und 3b. genannten Assets um körperliche Gegenstände handelt, werden
diese Assets hiermit übergeben, indem der Verkäufer diese nur noch für den Käufer ab sofort verwahrt. Der Verkäufer wird auschließlich dem Käufer den Zugang zu den in der EDV oder sonstwie gespeicherten Daten
gestatten.

		
	 b.      To the extent that such Assets are in the physical possession of third parties, the Seller hereby
assigns to the Purchaser its claim for repossession. The Purchaser accepts the assignment.
	  	 b.      Soweit solche Assets im Besitz von Dritten stehen, tritt der Verkäufer hiermit seinen
Herausgabeanspruch an den Käufer ab. Der Käufer nimmt diese Abtretung an.

		
	 c.      To the extent that the Seller has an expectancy right regarding such Assets, e.g. in connection with
retention of title, the Seller hereby assigns this expectancy right to the Purchaser. The Purchaser accepts the assignment.
	  	 c.      Soweit der Verkäufer ein Anwartschaftsrecht an solchen Assets hat, etwa im Zusammenhang mit einem
Eigentumsvorbehalt, tritt der Verkäufer dieses Anwartschaftsrecht an den Käufer ab. Der Käufer nimmt diese Abtretung an.

		
	 d.      To the extent that intellectual property rights or rights relating to inventions underlying the
intellectual property rights, in particular patents and patent applications, transferred under this Agreement, are transferred under this Agreement, the Seller shall make all declarations and to do all acts that are necessary for the acquisition by
the Purchaser of exclusive legal position with respect to these rights and for the registration of the transfer of rights in the relevant registers.
	  	 d.      Soweit nach diesem Vertrag gewerbliche Schutzrechte oder Rechte an Erfindungen, die den nach diesem
Vertrag übertragenen gewerblichen Schutzrechten, insbesondere Patenten und Patentanmeldungen, zu Grunde liegen, übertragen werden, hat der Verkäufer alle Erklärungen abzugeben und alle Handlungen vorzunehmen, die zum Erwerb der
exklusiven Rechtstellung in Bezug auf diese Rechte durch den Käufer und zur Eintragung des Rechtsübergangs in das jeweilige Register erforderlich sind.

		
	 e.      To the extent that contracts are assigned under this Agreement, the
	  	 e.      Soweit nach diesem Vertrag Verträge übertragen werden, wird der Verkäufer alle
Anstrengungen unternehmen,

  

 –6/6– 

			
	 Seller will use best efforts to procure the required consent of the other contractual party without delay. As long as the other contractual party has not granted,
or if it has rejected, its required consent to the assignment of the respective contract, the Seller and the Purchaser in their internal relationship will treat, and be treated by, each other as if the assignment of the agreement was effective. In
this case, the Seller will remain the contractual party of the respective contract externally and will fulfil the contract in the internal relationship for the account of the Purchaser; the necessary costs incurred in this respect shall be
reimbursed by the Purchaser to the Seller against provision of proof. Any termination of such a contract prior to September 30, 2005 requires the Purchaser’s consent.
	  	 um die notwendige Zustimmung der jeweils anderen Vertragspartei unverzüglich zu erlangen. Solange die jeweils andere Vertragspartei ihre notwendige Zustimmung
zu der Übertragung des jeweiligen Vertrages auf den Käufer nicht erteilt oder wenn sie diese verweigert hat, werden sich der Verkäufer und der Käufer im Innenverhältnis so verhalten und behandeln lassen, als ob die
Übemahme des Vertrages wirksam vollzogen wäre. In diesem Fall wird der Verkäufer im Außenverhältnis Vertragspartei des jeweiligen Vertrages bleiben und den jeweiligen Vertrag im Innenverhältnis für Rechnung des
Käufers erfüllen; die daraus entstehenden notwendigen Kosten hat der Käufer dem Verkäufer gegen Nachweis zu ersetzen. Die Kündigung eines solchen Vertrages vor dem 30. September 2005 durch den Verkäufer bedarf der
Zustimmung des Käufers.

		
	 f.       Should the transfer of an Asset under this Agreement not be effective, the Seller shall take all
actions that are necessary to effect the transfer.
	  	 f.       Sollte die Übertragung eines Assets nach diesem Vertrag nicht wirksam sein, hat der
Verkäufer alle Handlunen vorzunehmen, die zu einer wirksamen Übertragung erforderlich sind.

		
	 6.      All guarantees, warranties, compensation and similar rights of the Seller with regard to the Assets that
are transferred or assigned to the Purchaser pursuant to this Sec. 1 are hereby assigned to the Purchaser.
	  	 6.      Alle Garantien, Gewährleistungen, Entschädigungen und ähnlichen Rechte des
Verkäufers im Hinblick auf Assets, die an den Käufer gemäß diesem § 1 übereignet oder abgetreten werden, werden hiermit an den Käufer abgetreten.

		
	 7.      The Purchaser is aware that part of movable tangible assets located at the Seller’s premises at
Max-Lebsche-Platz 32 in 81377 Munich
	  	 7.      Dem Käufer ist bekannt, dass ein Teil der beweglichen Sachen, die sich in dem Anwesen des
Verkäufers in Max-Lebsche-Platz 32 in 81377

  

 –7/7– 

			
	 are subject to the landlord’s lien of GRH Beteiligungs GmbH & Co. 2. Verwaltungs KG, Neuburgerstr. 76, 94032 Passau
	  	 München befinden, dem Vermieterpfandrecht der GRH Beteiligungs GmbH & Co. 2. Verwaltungs KG, Neuburgerstr. 76, 94032 Passau
unterliegt.

		
	 8.      The Purchaser is aware that a part of the inventory is owned by third parties. These are movable
tangible assets leased from the companies LeaseTrend AG, Hamburg and UVW Leasing GmbH, 76275 Ettlingen. The Seller shall terminate these leasing contracts and make the leased items available to the Purchaser for use until the effective time of the
termination of the leasing contracts. The consideration is already included in the Purchase Price pursuant to Sec. 2.
	  	 8.      Dem Käufer ist bekannt, dass ein Teil des Inventars im Eigentum Dritter steht. Es handelt sich
dabei um bewegliche Gegenstände, die von den Firmen LeaseTrend AG, Hamburg und UVW Leasing GmbH, 76275 Ettlingen geleast sind. Der Verkäufer verpflichtet sich, diese Leasingverträge zu kündigen und die geleasten Gegenstände
bis zur wirksamen Beendigung des Leasingverhältnisses dem Käufer zur Nutzung zur Verfügung zu stellen. Die Gegenleistung des Käufers ist in dem Kaufpreis gemäß § 2 bereits enthalten.

		
	 9.      Axxima is the sole shareholder of the Hungarian company Vichem Chemie Kutato Kft, Herman Ottó
út 15, 1022 Budapest (“Vichem”). The Managing Director is Mr. Prof. Dr. Gyorgy Keri PhD. D. Sc, Budapest. The shares in Vichem are explicitly excluded from the transfer of the Assets under this Agreement and will remain
with the Seller. The Seller will make an effort to offer the takeover of the shares in Vichem to Prof. Dr. Keri. The Seller will use best efforts to procure that (i) all employees of Vichem will enter into an agreement with Vichem on the
assignment to Vichem of all their rights pertaining to inventions that underly the intellectual property rights to be transferred under this Agreement, in particular
	  	 9.      Axxima ist die alleinige Gesellschafterin der Fa. Vichem Chemie Kutató Kft, Herman Ottó
út 15, 1022 Budapest LVichenV). Geschäftsführer ist Herr Prof. Dr. György Keri PhD. D. Sc, Budapest. Die Geschäftsanteile an Vichem werden explizit von der Übertragung von Assets nach diesem Vertrag an den Käufer
ausgeschlossen und verbleiben beim Verkäufer. Der Verkäufer wird sich bemühen, die Geschäftsanteile an Vichem dem Geschäftsführer Herrn Prof. Keri zur Übernahme anzubieten. Der Verkäufer wird alle
Anstrengungen unternehmen, um zu erreichen, dass (i) alle Arbeitnehmer der Vichem mit der Vichem eine schriftliche Vereinbarung abschließen über die Abtretung ihrer sämtlichen Rechte an Erfindungen an die

  

 –8/8– 

			
	 patents and patent applications, to the extent that those rights have not been validly transferred to Vichem, and (ii) these rights are assigned by Vichem to the
Purchaser.
	  	 Vichem, die den nach diesem Vertrag zu übertragenden gewerblichen Schutzrechten, insbesondere Patenten und Patentanmeldungen, zu Grunde liegen, soweit sie
nicht bereits wirksam auf die Vichem übergegangen sind, und (ii) diese Rechte von der Vichem auf den Käufer übertragen werden.

		
	 10.    There exist agreements on ongoing research projects between Axxima on the one hand and Bayerische
Forschungsstiftung – BFS, Bundesministerium fur Bildung und Forschung – BMBF and with other institutions on the other hand. As outlined in the overview attached as Exhibit 1.10, grants in the amount of up to appr. 2.000.000 EUR can still
be drawn by Axxima. The Seller hereby assigns all rights under these agreements to the Purchaser (to the extent that the assignment is not excluded) and will take all actions in order to effect the transition of the respective agreements (be it by
way of assumption of contract, be it by way of conclusion of new agreements) without any liabilities of the Seller or of the Company that exist at the time of the opening of the insolvency proceedings vis-à-vis the institutions or any
contractual parties and the payment of all outstanding grants by the institutions to the Purchaser. The Purchaser accepts the assignment. Any and all liability of the Seller in connection with his obligations under this Sec. 1 para. 10 is
excluded.
	  	 10.    Zwischen der Axxima einerseits und der Bayerischen Forschungsstiftung – BFS –, dem Bundesministerium
fur Bildung und Forschung – BMBF – und weiteren Instituten (nachfolgend: Institutionen”) andererseits bestehen Verträge für laufende Forschungsprojekte. Gemäß der als Anlage 1.10 beigefügten Aufstellung
können noch Fördermittel bis zu rund 2.000.000 EUR abgerufen werden. Der Verkäufer tritt hiermit sämtliche Rechte aus diesen Verträgen an den Käufer ab (soweit die Abtretung nicht vertraglich ausgeschlossen ist) und
wird alles tun, um eine Überleitung der jeweiligen Verträge (sei es im Wege der Vertragsübernahme, sei es im Wege des Neuabschlusses) ohne im Zeitpunkt der Eröffnung des Insolvenzverfahrens bestehende Verbindlichkeiten des
Verkäufers bzw. der Gesellschaft gegenüber den Institutionen oder etwaigen Vertragspartnern sowie die Auszahlung aller noch ausstehender Fördermittel durch die Institutionen an den Käufer zu erreichen. Der Käufer nimmt die
Abtretung an. Jegliche Haftung des Verkäufers im Zusammenhang mit seinen Verpflichtungen gemäß diesem § 1 Abs. 10 wird ausgeschlossen.

  

 –9/9– 

			
	 Sec. 2
	  	§2
		
	 PURCHASE PRICE
	  	KAUFPREIS
		
	 1.      Purchaser shall pay to the Seller a purchase price in the amount of EUR 2,000,000.- in aggregate plus
statutory VAT (if applicable) for all Assets (the “Purchase Price”), to be paid on March 10, 2005 at the latest. If VAT is payable, the Purchaser shall only be obliged to pay the purchase price after receipt of an invoice in proper
form.
	  	 1.      Der Käufer zahlt an den Verkäufer einen Kaufpreis in Höhe von insgesamt EUR 2.000.000,-
zuzüglich etwa anfallender gesetzlicher Mehrwertsteuer für sämtliche Assets (“Kaufpreis”), fällig bis 10. März 2005. Falls Mehrwertsteuer anfällt, ist der Käufer nur zur Zahlung des Kaufpreises
verpflichtet, wenn er zuvor eine ordnungsgemäß ausgestellte Rechnung erhalten hat.

		
	 The purchase price shall be transfered to .bank account No. 652030181 at Bayerische Hypotheken- und Wechselbank AG, sort code 700 202 70.
	  	 Der Kaufpreis ist zu überweisen auf das Konto Nr. 652030181 bei der Bayerische Hypotheken- und Wechselbank AG München, BLZ 700 202
70.

		
	 Sec 3
	  	 §3

		
	 MILESTONE PAYMENTS
	  	 ZAHLUNG FÜR MEILENSTEINE

		
	 1.      In addition to the Purchase Price as set forth under Sec. 2, one time payments for the achievement of
milestones shall become due as follows:
	  	 1.      Zusätzlich zum Kaufpreis gem. § 2 werden im Falle des Erreichens der folgenden Meilensteine
einmalige Zahlungen wie folgt fällig:

		
	 a.      An amount of EUR 1,000,000.00 plus statutory VAT, if applicable, at the beginning of each of the first
phase I clinical studies (treatment of the first patient) by the Purchaser or GPC Biotech AG for the first three compounds that are covered by claims under the Axxima patent applications or patents listed in Exhibit 1.2 (1) that exist at the
time of the beginning of the respective phase I study and that are not covered by the
	  	 a.      Ein Betrag in Höhe von jeweils 1.000.000,00 EUR zuzüglich etwa anfallender gesetzlicher MwSt
bei Beginn der jeweils ersten klinischen Phase I Studie (Behandlung des ersten Patienten) durch den Käufer bzw. die GPC Biotech AG für die ersten drei Substanzen, welche zum Zeitpunkt des Beginns der jeweiligen Phase I Studie durch dann
bestehende Ansprüche der in Anlage 1.2(1) aufgeführten Axxima Patentanmeldungen

  

 –10/10– 

			
	 exception set out in paragraph 3.
	  	Óder Patente geschützt sind und die nicht unter die Ausnahmeregelung von Abs. 3 fallen.
		
	 b.      An amount of EUR 1,000,000.00 plus statutory VAT, if applicable, at the beginning of each of the first
phase II clinical studies (treatment of the first patient) by the Purchaser or GPC Biotech AG for the first three compounds that are covered by claims under the Axxima patent applications or patents listed in Exhibit 1.2 (1) that exist at the
time of the beginning of the respective phase II study and that are not covered by the exception set out in paragraph 3.
	  	 b.      Ein Betrag in Höne von jeweils 1.000.000,00 EUR zuzüglich etwa anfallender gesetzlicher MwSt
bei Beginn der jeweils ersten klinischen Phase II Studie (Behandlung des ersten Patienten) durch den Käufer bzw. die GPC Biotech AG für die ersten drei Substanzen, welche zum Zeitpunkt des Beginns der jeweiligen Phase II Studie durch dann
bestehende Ansprüche der in Anlage 1.2 (1) aufgeführten Axxima Patentanmeldungen oder Patente geschützt sind und die nicht unter die Ausnahmeregelung von Abs. 3 fallen.

		
	 c.      An amount of EUR 1,000,000.00 plus statutory VAT, if applicable, at the beginning of each of the first
phase III clinical studies (treatment of the first patient) by the Purchaser or GPC Biotech AG for the first three compounds that are covered by claims under the Axxima patent applications or patents listed in Exhibit 1.2 (1) that exist at the
time of the beginning of the respective phase III study and that are not covered by the exception set out in paragraph 3.
	  	 c.      Ein Betrag in Höhe von jeweils 1.000.000,00 EUR zuzüglich etwa anfallender gesetzlicher MwSt
bei Beginn der jeweils ersten klinischen Phase III Studie (Behandlung des ersten Patienten) durch den Käufer bzw. die GPC Biotech AG für die ersten drei Substanzen, welche zum Zeitpunkt des Beginns der jeweiligen Phase III Studie durch
dann bestehende Ansprüche der in Anlage 1.2(1) aufgeführten Axxima Patentanmeldungen oder Patente geschützt sind und die nicht unter die Ausnahmeregelung von Abs. 3 fallen.

		
	 2.      The aforementioned payments upon achievement of the milestones 1 .a. to 1 .C. by the Purchaser or GPC
Biotech AG shall become due only once per clinical study phase per substance. In aggregate, a maximum amount of
	  	 2.      Die vorgenannten Zahlungen bei Erreichen der Meilensteine 1.a. bis I.C. durch den Käufer bzw. die
GPC Biotech AG werden jeweils nur einmal pro klinische Phase für die jeweilige Substanz zur Zahlung fällig. Insgesamt 

  

 –11/11– 

			
		
	 EUR 9,000,000.- plus statutory VAT, if applicable, will become due, since the milestones 1 .a. to 1 .c. become due up to three times. The milestones shall also
become due for payment by the Purchaser or GPC Biotech AG if the Purchaser or GPC Biotech AG outlicenses or sells rights pertaining to the Axxima patent applications on an exclusive basis and the respective licensee or purchaser achieves the
respective milestones. The Purchaser or GPC Biotech AG shall inform the Seller on a biannual basis of the status of research for each of the research projects pertaining to the Axxima property rights insofar as such projects could trigger payment
obligations under this Sec. 3. The Purchaser or GPC Biotech AG will strive to impose such information obligation on any licensees or acquirers of these “rights by the Seller or GPC Biotech AG and will in any event ensure by way of contractual
arrangements with them that the achievement of the milestones can be checked by GPC Biotech AG or the Purchaser.
	  	 eine Summe von höchstens EUR 9.000.000,- zuzüglich etwa anfallender gesetzlicher MwSt fällig, da die Meilensteine 1 .a. bis 1 .c. bis zu dreimal
fällig werden. Die Meilensteine sind von dem Käufer bzw. GPC Biotech AG auch zu zahlen, wenn der Käufer bzw. die GPC Biotech AG Rechte an den Axxima Patentanmeldungen exklusiv auslizenziert oder verkauft und der jeweilige Lizenznehmer
bzw. Erwerber der Rechte die jeweiligen Meilensteine erreicht hat. Der Käufer bzw. die GPC Biotech AG wird den Verkäufer 1/2 jährlich Über den Stand der Forschung für alle unter die Axximachutzrechte fallenden
Forschungsvorhaben informieren, soweit diese Zahlungspflichten nach diesem § 3 auslösen könnten. Der Käufer bzw. die GPC Biotech AG werden sich bemühen, eine solche Informationspflicht auch etwaigen Lizenznehmern oder
Erwerbern der Rechte aufzuerlegen und werden in jedem Fall durch entsprechende vertragliche Abreden mit diesen die Überprüfbarkeit der Erreichung der Meilensteine durch GPC Biotech AG bzw. den Käufer
sicherstellen.

		
	 3.      If at the time of the opening of the insolvency proceedings a compound is already protected by patents
or prior patent applications of GPC Biotech AG or GPC Biotech Inc. or by rights of GPC Biotech AG or GPC Biotech Inc. with respect to inventions underlying the intellectual property rights to be transferred under this Agreement, in particular
patents and patent applications, it shall not be considered for a milestone payment.
	  	 3.      Wenn eine Substanz zum Zeitpunkt der Eröffnung des Insolvenzverfahrens bereits durch bestehende
Patente oder vorrangige Patentanmeldungen der GPC Biotech AG bzw. der GPC Biotech Inc. oder Rechte der GPC Biotech AG bzw. der GPC Biotech Inc. an Erfindungen, die den nach diesem Vertrag zu übertragenden gewerblichen Schutzrechten,
insbesondere Patenten und Patentanmeldungen, zu Grunde liegen, abgedeckt wird, kommt sie fur eine Meilensteinzahlung nicht in Betracht.

		
	 4.      If the intellectual property rights to be
	  	 4.      Wenn die nach diesem Vertrag zu übertragenden

  

 –12/12– 

			
	 transferred under this Agreement (in particular the Axxima patent applications set out in Exhibit 1.2 (1)) and rights with respect to inventions un- derlying the
intellectual property rights to be transferred under this Agreement, in particular patents and patent applications, have not been transferred to the Purchaser on an exclusive basis and the Purchaser or GPC Biotech AG have incurred expenditures after
the conclusion of this Agreement for the acquisition of such exclusive rights, then such expenditures can be set-off against the milestone payments.
	  	 gewerblichen Schutzrechte (insbesondere die in Anlage 1.2(1) aufgefuhrten Axxima Patentanmeldungen) undRechte an Erfindungen, die den nach diesem Vertrag zu
übertragenden gewerblichen Schutzrechten, insbesondere Patenten und Patentanmeldungen, zugrunde liegen, nicht durch diesen Vertrag exklusiv an den Käufer übergegangen sind und dem Käufer oder der GPC Biotech AG nach Abschluss
dieses Vertrages Aufwendungen für den Erwerb dieser exklusiven Rechte entstanden sind, so können diese Aufwendungen mit den Meilensteinzahlungen verrechnet werden.

		
	 5,      This Agreement is concluded subject to the condition precedent that the Purchaser provides a declaration
by GPC Biotech AG securing the payment of the purchase price and of the milestones and on the assumption of own obligations under this Agreement.
	  	 5.      Dieser Vertrag wird unter der aufschiebenden Bedingung geschlossen, dass der Käufer eine
Erklärung der GPC Biotech AG über die Sicherstellung der Zahlung des Kaufpreises und der Meilensteine und
der Übernahme eigener Verpflichtungern nach diesem Vertrag beibnimgt.

		
	 6.      The Purchaser shall inform the Seller in writing within 30 days after a milestone has been achieved and
request an invoice.
	  	 6.      Der Käufer verpflichtet sich, binnen 30 Tage nach Erreichen eines Meilensteines den Verkäufer
schriftlich zu informieren und ihn um eine Rechnung zu bitten.

		
	 7.      If VAT must be paid with regard to payments pursuant to this Sec. 3, the Purchaser shall only be obliged
to make the payment after receipt of an invoice in proper form.
	  	 7       Falls in Bezug auf Zahlungen gemäß diesem § 3 Mehrwertsteuer anfällt, ist der
Käufer nur zur Zahlung verpflichtet, wenn er zuvor eine ordnungsgemäß ausgestellte Rechnung erhalten hat.

		
	 Sec. 4
	  	 §4

		
	 GUARANTEES
	  	 GARANTIEN

		
	 1.      The Seller guarantees vis-avis the Purchaser by means of an independent guarantee undertaking
according
	  	 1.      Der Verkäufer garantiert dem Käufer im Wege eines selbstständigen Garantieversprechens
gemäß § 311 BGB Folgendes:

  

 –13/13– 

			
	 to Sec. 311 German Civil Code (BGB) as follows:
	  	
		
	 a.      Except as disclosed in this Agreement, the Seller is the sole owner or holder of all the Assets and the
Assets are free and clear of any and all third party rights or claims.
	  	 a.      Außer in den in diesem Vertrag angeführten Fällen ist der Verkäufer alleiniger
Eigentümer bzw. Inhaber aller Assets und diese sind frei von jeglichen Rechten oder Ansprüchen Dritter.

		
	 b.      The Seller has taken all steps necessary to preserve the confidential nature of all material
confidential information (including, without limitation, any proprietary information) with respect to the Assets, including but not limited to the manufacturing or marketing of any of the products or services.
	  	 b.      Der Verkäufer hat alle erforderlichen Schritte l um unternommen, um die vertrauliche Natur aller
wesentlichen vertraulichen Informationen im Hinblick auf die Vermögenswerte zu bewahren (einschließlich, ohne jedoch darauf beschränkt zu sein, aller gesetzlich geschützten Informationen), einschließlich, ohne jedoch
darauf beschränkt zu sein, Informationen zur Herstellung oder Vermarktung solcher Produkte oder Dienstleistungen.

		
	 c.      The validly appointed creditors’ committee has approved of the conclusion of this Agreement and the
sale and transfer of the Assets herunder.
	  	 c.      Der wirksam bestellte Gläubigerausschuss hat dem Abschluss dieses Vertrages sowie dem Verkauf und
der Übereignung der Assets zugestimmt.

		
	 2.      The parties agree that none of the guarantees contained in this Agreement constitutes a guarantee with
respect to the quality of the object within the meaning of Sec. 444 2nd alternative German Civil Code (BGB) in the version effective as of January 1, 2002 nor a guarantee with respect to the quality within the meaning of Sec. 443 BGB in the
version effective as of January 1, 2002.
	  	 2.      Die Vertragsparteien stimmen überein, dass keine der in dieser Vereinbarung enthaltenen Garantien
eine Garantie für die Beschaffenheit der Sache im Sinne von § 444 zweite Alternative BGB (in der Fassung seit 1.1.2002) oder eine Beschaffenheitsgarantie im Sinne von § 443 BGB in der Fassung seit 1.1.2002
darstellt.

		
	 3.      Liability shall be limited as follows: The Insolvency Receiver shall not be personally liable. With the
exception of the non-fault guarantee in Sec 4 para. 1a., the liability of the Seller
	  	 3.      Die Haftung ist wie folgt begrenzt: Der Insolvenzverwalter haftet nicht persönlich. Mit Ausnahme
der verschuldensunabhängigen Garantie in § 4 Abs. 1 a. haftet der Verkäufer mit der von ihm

  

 –14/14– 

			
	 with regard to the insolvency estate is limited to gross negligence and wilful misconduct.
	  	verwalteten Masse nur für grobe Fahrlässigkeit und Vorsatz.
		
	 SEC. 5
	  	§5
		
	 CONTRACT OF TENANCY
	  	MIETVERTRAG
		
	The Seller shall terminate the Lease Agreement of tenancy concerning the rented premises Max-Lebsche-Platz 32 in due time effective as per September 30, 2005 and discharge all obligations
of the Company under the contract of tenancy, including but not limited to the obligation to return the premises pursuant to the Lease Agreement, until the effective end date of the rental relationship. The Seller will make available the premises to
the Purchaser for use at the Purchaser’s option for the period from March 1, 2005 until September 30, 2005. The Purchaser will pay a contribution towards expenses in the amount of EUR 25,000.00 plus VAT per month for the period it
exercises its right of use; this amount shall be due in advance on the third day of each month; the pro-rated contribution towards expenses for the month of March 2005 shall be due on March 10, 2005. The Purchaser does not assume any
obligations in the relationship vis-à-vis the landlord. To the extent that claims are made against the Purchaser by the landlord in connection with the tenancy relationship, the Seller shall indemnify the Purchaser from such claims. The
Purchaser has the right to terminate the use of the premises at any time by giving one week’s notice.	  	Der Verkäufer verpflichtet sich, den Mietvertrag hinsichtlich der Mieträume Max-Lebsche-Platz 32 in München fristgerecht zum 30. September 2005 zu kündigen und alle sich
aus dem Mietvertrag ergebenden Verpflichtungen der Gesellschaft vom 1. März 2005 bis zur wirksamen Beendigung des Mietverhaltnisses einschließlich der Verpflichtung zur vertragsgemäßen Rückgabe zu erfüllen. Der
Verkäufer wird dem Käufer die Mieträume nach dessen Wahl für den Zeitraum bis 30. September 2005 zur Nutzung zur Verfügung stellen. Der Käufer wird für den Zeitraum der tatsächlichen Inanspruchnahme seines
Nutzungsrechts hierfür einen Unkostenbeitrag von EUR 25.000,00 zuzüglich Mehrwertsteuer pro Monat bezahlen; dieser Betrag wird am dritten Tag eines jeden Monats im voraus fällig; der anteilige Unkostenbeitrag für den Monat
März 2005 wird am 10. März 2005 fällig. Im Verhältnis zum Vermieter übernimmt der Käufer keinerlei Verpflichtungen. Soweit der Käufer vom Vermieter im Zusammenhang mit dem Mietverhältnis in Anspruch genommen
wird, stellt der Verkäufer den Käufer von derartigen Ansprüchen frei. Der Käufer ist berechtigt, die Nutzung der Mieträume jederzeit mit einer Kündigungsfrist von einer Woche zum Monatsende zu beenden.

  

 –15/15– 

			
	 SEC. 6
	  	 §6

		
	 NO FINDER’S COMMISSION
	  	 KEINE VERMITTLUNGSGEBÜHR

		
	 No negotiations relating to this Agreement have been carried on by any of the persons acting on behalf of the Seller in such a manner that would give rise to any
valid claim against Purchaser for any brokerage or finder’s commission, fee or similar compensation.
	  	 Keine der Verhandlungen im Rahmen dieser Vereinbarung sind von den für oder im Namen des Verkäufers handelnden Personen derart durchgeführt worden,
dass diese eine Grundlage für Forderungen gegen den Käufer in Bezug auf Makler- oder Vermittlungsgebühren, Kommissionen oder sonstige Vergütung haben.

		
	 SEC. 7
	  	 §7

		
	 CONFIDENTIALITY
	  	 VERTRAULICHKEIT

		
	 1.      Except as required by applicable law, the Seller shall not make any public announcement in
respect of this. agreement or the transactions contemplated hereby without the prior written consent of Purchaser.
	  	 1.      Sofern nicht gesetzlich vorgeschrieben, gibt der Verkäufer diese Vereinbarung und die darin
behandelten Transaktionen nur nach vorherigem schriftlichen Einverständnis des Käufers öffentlich bekannt.

		
	 2.      The parties of this Agreement will keep the existence and the content of this Agreement as well as all
circumstances related hereto confidential vis à vis third parties, excluding GPC Biotech AG, the Local Court of Munich Insolvency Court (“AG München Insolvenzgericht”) and the creditors’ committee as well as the
creditors’ assembly of the Company, unless disclosure to third parties is required by law, public authority or the provisions of a stock exchange or as reasonably required as necessary to inform the employees.
	  	 2.      Die Vertragsparteien behandeln die Existenz und den Inhalt dieses Vertrags sowie alle damit
zusammenhängenden Umstände gegenüber Dritten mit Ausnahme der GPC Biotech AG, dem AG München Insolvenzgericht und dem Gläubigerausschuss sowie der Gäubigerversammlung der Gesellschaft als vertraulich, es sei denn, eine
Offenlegung gegenüber Dritten ist gesetzlich, behördlich oder nach den Regeln einer Börse vorgeschrieben, oder sie werden in einem erforderlichen und angemessenen Umfang offen gelegt, um die Angestellten zu
informieren.

		
	 3.      This confidentiality obligation shall not apply vis-à-vis persons who, according to the law, are
obliged to keep information confidential if and to the extent that a party to this Agreement discloses confidential information
	  	 3.      Diese Vertraulichkeitsverpflichtung gilt gegenüber Personen, die gesetzlich verpflichtet sind,
Informationen vertraulich zu behandeln nicht, sofern und in dem Umfang, in dem eine Vertragspartei vertrauliche Informationen offen legt, um ihre

  

 –16/16– 

			
	 in order to pursue its legitimate interests. In particular, this confidentiality obligation shall not apply in connection with mergers and acquisitions of GPC
Biotech AG and its as- sociated enterprises (be it as purchaser, seller or target company) and in connection with financing transactions.
	  	 legitimen Interessen wahrzunehmen. Insbesondere gilt diese Vertraulichkeitsverpflichtung nicht im Zusammenhang mit Fusionen und Akquisitionen der GPC Biotech AG
und ihrer verbundenen Untemehmen (sei es als Käufer, Verkäufer oder Zielgesellschaft) sowie im Zusammenhang mit Finanzierungstransaktionen.

		
	 4.      The Purchaser is aware that the Seller has negotiated with third parties regarding the conclusion of a
similar agreement and provided information in this context. Such information has only been provided under protection of a common non disclosure agreement. The Seller shall use best efforts to get back such information or to have such information
destroyed
	  	 4.      Dem Käufer ist bekannt, dass der Verkäufer mit einigen dritten Parteien über den
Abschluss eines vergleichbaren Vertrags verhandelt und in diesem Zusammenhang Informationen zur Verfügung gestellt hat. Diese Informationsgewährung erfolgte jedoch nur unter dem Schutz einer üblichen Geheimhaitungsvereinbarung. Der
Verkäufer wird alle Anstrengungen unternehmen, diese Informationen zurückzuerhalten oder vernichten zu lassen.

		
	 SEC. 8
	  	 §8

		
	 FURTHER ACTIONS AND OBLIGATIONS
	  	 WEITERE MASSNAHMEN UND VERPFLICHTUNGEN

		
	 1.      The Seller agrees to use all reasonable efforts and to do all things necessary, proper or advisable to
consummate the transactions contemplated hereby.
	  	 1.      Der Verkäufer verpflichtet sich, alle angemessenen Anstrengungen zu unternehmen und alle
erforderlichen Maßnahmen zu ergreifen, die geeignet und ratsam sind, um diesen Vertrag umzusetzen.

		
	 2.      The Seller will without delay file or supply, or cause to be filed or supplied, all applications,
notifications and information required to be filed or supplied pursuant to applicable law in connection with the Agreement, the sale and transfer of the Assets and the consummation, including but not limited to signing over of the
intellectual
	  	 2.      Der Verkäufer wird unverzüglich alle notwendigen Anträge, Benachrichtigungen und
Informationen in Zusammenhang mit diesem Vertrag, dem Verkauf oder der Übertragung der Assets oder der Umsetzung einreichen oder vorlegen oder deren Einreichung oder Vorlage veranlassen, insbesondere der Umschreibung der Schutzrechte. Der
Verkufer

  

 –17/17– 

			
	 property rights. Upon the Purchaser’s request, the Seller shall use best efforts to support the Purchaser in the continuation of all advisory services
regarding the intellectual property of the Company.
	  	 wird den Käufer auf dessen Verlangen hin, nach besten Kräften bei der Übernahme aller Beratungsmandate im Hinblick auf die Schutzrechte der
Gesellschaft unterstützen.

		
	 3.      TVM V Life Science Ventures GmbH & Co. KG, Munich, has assigned all claims under the insolvency
estate loan dated January 3, 2005, under the agreement attached as Exhibit 8.3 to the Purchaser by way of assumption of contract. The Seller shall consent to the assumption of contract and pay the loan amount of EUR 330,000.00 plus contractually
agreed interest to the Seller immediately after receipt of the purchase price pursuant to Sec. 2.1 of this Agreement.
	  	 3.      TVM V Life Science Ventures GmbH & Co. KG, München, hat sämtliche Ansprüche aus dem
Massedarlehen vom 3. Januar 2005 gemäß der als Anlage 8.3 beigefügten Vereinbarung an den Käufer im Wege der Vertragsübernahme abgetreten. Der Verkäufer verpflichtet sich, der Vertragsübernahme zuzustimmen und
unmittelbar nach Erhalt des Kaufpreises gemäß § 2.1 dieses Vertrages den Darlehensbetrag von EUR 330.000,00 zuzüglich der vertraglich vereinbarten Zinsen an den Käufer zu zahlen.

		
	 SEC. 9
	  	 §9

		
	 EMPLOYEES
	  	 ARBEITNEHMER

		
	 1. The parties agree that only the employees named in Exhibit 9.1(1) shall be taken over by GPC Biotech AG and none of the employees shall be taken over by the
Purchaser. GPC Biotech AG has offered the conclusion of employment agreements to these employees with a time limit as per March 4, 2005, conditional on the effectiveness of this Agreement, or will do so within a short period of time after the
conclusion of this Agreement. The Seller shall terminate the employment relationships of the employees named in Exhibit 9.1(2) who are not to be taken over by either of
	  	 1. Die Parteien stimmen darin überein, dass ausschließlich die in der Anlage 9.1(1) namentlich genannten Arbeitnehmer von der GPC Biotech AG
übernommen werden sollen und kein Arbeitnehmer von dem Käufer übernommen werden soll. Die GPC Biotech AG hat diesen Arbeitnehmern unter Fristsetzung bis zum Ablauf des 4. März 2005 den Abschluss von Anstellungsverträgen,
bedingt durch das Wirksamwerden dieses Kaufvertrages, angeboten bzw. wird dies innerhalb kurzer Zeit nach Abschluss dieses Vertrages tun. Der Verkäufer wird die Arbeitsverhältnisse der in Anlage

  

 –18/18– 

			
	 the Purchaser or GPC Biotech AG and will use best efforts to procure that these employees leave their employment without asserting any claims against the Purchaser
or GPC Biotech AG. The Seller and the Purchaser shall act together in order to terminate such employment relationships in an as rapid and cost-efficient manner as possible.
	  	 9.1(2) namentlich bezeichneten, weder von dem Käufer, noch der GPC Biotech AG zu übernehmenden Arbeitnehmer kündigen und alle Anstrengungen
unternehmen um zu bewirken, dass diese Arbeitnehmer aus ihrem Arbeitsverhältnis ausscheiden, ohne Ansprüche gegen den Käufer oder die GPC Biotech AG geltend zu machen. Verkäufer und Käufer wirken zusammen, um derartige
Arbeitsverhältnisse möglichst kurzfristig und köstengünstig zu beenden.

		
	 2.      The costs for the satisfaction of claims of the employees (Exhibits 9.1(1) and 9.1(2) shall be allocated
among the parties as follows:
	  	 2.      Die Kosten für die Erfüllung von Ansprüchen der Arbeitnehmer (Anlagen 9.1(1) und 9.1(2))
werden zwischen den Parteien wie folgt aufgeteilt:

		
	 a)      The Seller shall bear the costs for the satisfaction of claims of the employees set out in Exhibit
9.1(1) to the extent that such claims accrue or are earned up until this Agreement becomes effective, including remuneration claims, expectancy rights, holiday, special payments, claims to receive payment of compensation for employee inventions,
bonus, commission and royalty payments, social security contributions, wage taxes and other claims of the employees. The Seller shall terminate the employment relationships of the employees set out in Exhibit 9.1(1) who have not accepted the
contractual offer by GPC Biotech AG by March 4, 2005, after being so requested in writing by the Purchaser without delay as per the next possible effective time. With respect to these employees, the provision set out under b) below shall
apply
	  	 a)      Der Verkäufer hat die Kosten für die Erfüllung von Ansprüchen der in der Anlage
9.1(1) benannten Arbeitnehmer zu tragen, soweit diese Anspruche bis zum Wirksamwerden dieses Vertrages entstehen oder (anteilig) erdient werden und zwar unter Einschluss von Vergütungsansprüchen, Anwartschaften, Urlaub, Sonderzahlungen,
Ansprüchen auf Zahlung der Vergütung fur Arbeitnehmererfindungen, Bonus-, Provisions- und Tantiemezahlungen, Sozialversicherungsbeiträgen, Lohnsteuern sowie sonstigen Ansprüchen der Arbeitnehmer. Die Arbeitsverhältnisse der
in der Anlage 9.1(1) benannten Arbeitnehmer, die das Vertragsangebot der GPC Biotech AG nicht bis zum 4. März 2005 annehmen, hat der Verkäufer nach schriftlicher Aufforderung durch den Käufer umgehend zum nächstmöglichen
Zeitpunkt zu kündigen. In Bezug

  

 –19/19– 

			
	 insofar as the Seller shall bear ongoing remuneration claims of these employees during the statutory termination periods. To the extent that the Seller must bear
costs pursuant to the provision set out above, the Seller shall indemnify the Purchaser and GPC Biotech AG and reimburse to them all costs in this respect to the extent incurred by any one of them nonetheless, including costs for the defence against
such claims, if any.
	  	 auf diese Arbeitnehmer gilt die nachfolgend unter b) bezeichnete Regelung insoweit, als der Verkäufer für laufende Gehaltsansprüche dieser
Arbeitnehmer innerhalb der gesetzlichen Kündigungsfristen aufzukommen hat. Soweit nach vorstehender Regelung der Verkäufer die Kosten zu tragen hat, stellt er den Käufer und GPC Biotech AG frei und erstattet ihnen sämtliche damit
zusammenhängenden Kosten, soweit diese gleichwohl bei ihnen anfallen, und zwar einschließlich etwaiger Kosten für die Abwehr derartiger Ansprüche.

		
	 b)      The Seller shall bear the costs for the employment of the employees set put in Exhibit 9.1(2) (who shall
be terminated) up until the end date of the respective statutory notice periods (sections 113 Insolvency Code, 622 Civil Code). In addition, the Seller shall bear costs for severance payments to these employees, but only up to an aggregate amount of
EUR 150,000; the Purchaser shall bear any additional costs for severance payments to these employees, provided that it has consented to these severance payments in advance. To the extent that the Seller must bear costs pursuant to the provision set
out above, the Seller shall indemnify the Purchaser and GPC Biotech AG and reimburse to them all costs in this respect to the extent incurred by any one of them nonetheless, including costs for the defence against such claims, if
any.
	  	 b)      Die Kosten der Beschäftigung von in der Anlage 9.1 (2) benannten, zu kündigenden Arbeitnehmem
hat der Verkäufer bis zum Ablauf der jeweiligen gesetzlichen Kündigungsfristen zu tragen (§§ 113 InsO, 622 BGB). Kosten für Abfindungszahlungen an diese Arbeitnehmer trägt der Verkäufer zusätzlich, jedoch nur
bis zu einem Gesamtbetrag von EUR 150.000; darüber hinaus gehende Kosten für Abfindungszahlungen an diese Arbeitnehmer trägt der Käufer, vorausgesetzt, dass er diesen Abfindungen vorab schriftlich zugestimmt hat. Soweit nach
vorstehender Regelung der Verkäufer die Kosten zu tragen hat, stellt er den Käufer und GPC Biotech AG frei und erstattet ihnen sämtliche damit zusammenhängenden Kosten, soweit diese gleichwohl bei ihnen anfallen, und zwar
einschließlich etwaiger Kosten für die Abwehr derartiger Ansprüche.

  

 –20/20– 

			
	 3.      The Seller will (i) enter into a written agreement with all employees (who are set out in Exhibit 9.1(2)
and who receive a severance payment) on the assignment to the Seller of all their rights pertaining to inventions that underly the intellectual property rights to be transferred under this Agreement, in particular patents and patent applications, to
the extent that those rights have not been validly transferred to the Company and (ii) assign these rights to the Purchaser.
	  	 3.      Der Verkäufer wird (i) mit allen Arbeitnehmern, die in Anlage 9.1(2) aufgeführt sind und eine
Abfindung erhalten, eine schriftliche Vereinbarung abschließen über die Abtretung ihrer sämtlichen Rechte an Erfindungen an den Verkäufer, die den nach diesem Vertrag zu übertragenden gewerblichen Schutzrechten,
insbesondere Patenten und Patentanmeldungen, zu Grunde liegen, soweit sie nicht bereits wirksam auf die Gesellschaft übergegangen sind, und (ii) diese Rechte auf den Käufer übertragen.

		
	 §10  
	  	 §10  

	RESCISSION RIGHT	  	RUCKTRITTSRECHT
		
	The Purchaser may rescind this Agreement in writing by way of a declaration of rescission until the end of March 2, 2005 (time of the making, not of the receipt of the
declaration).	  	Der Käufer kann durch schriftliche Rücktrittserklärung bis zum Ablauf des 2. März 2005 (Zeitpunkt der Abgabe der Erklärung, nicht des Zugangs) von diesem Vertrag
zurücktreten.
		
	 SEC.11
	  	 §11  

	 APPROVALBY CREDITORS’ COMMITTEE
	  	 ZUSTIMMUNG    DES    GLÄUBIGERAUSSCHUSSES

		
	The creditors’ committee has already approved of the conclusion of this Agreement. Such approval is attached as Exhibit 11.	  	Der wirksam bestellte Gläubigerausschuss hat dem Abschluss dieses Vertrags bereits zugestimmt. Die Zustimmung ist in Anlage 11 beigefügt.
		
	 SEC.12
	  	 §12  

	 MISCELLANEOUS
	  	 VERSCHIEDENES

		
	 1.      The headings contained in this Agreement are for purposes of convenience only and shall not affect the
meaning or interpretation of this
	  	 1.      Die in dieser Vereinbarung enthaltenen Überschriften dienen allein der Übersichtlichkeit und
wirken sich in keiner Weise auf Bedeutung und

  

 –21/21– 

			
	 Agreement in any way.
	  	 Auslegung des Vertrags.

		
	 2.      This Agreement (including the Exhibits hereto), constitutes the entire agreement and supersedes all
prior agreements and understandings, both written and oral, between the parties with respect to the subject matter hereof.
	  	 2.      Diese Vereinbarung (einschließlich ihrer Anhänge) stellt die gesamte Vereinbarung dar und
ersetzt alle früheren mündlichen und schriftlichen Vereinbarungen und Übereinkünfte zwischen den Vertragsparteien.

		
	 3.      This Agreement shall be governed by the laws of the Federal Republic of Germany. The application of the
EGBGB (Introductory Code to the German Civil Code) shall be ex- cluded. The UN Sales Convention (CISG) shall not be applicable.
	  	 3.      Diese Vereinbarung unterliegt dem Recht der Bundesrepublik Deutschland. Das EGBGB
(Einführungsgesetz zum Bürgerlichen Gesetzbuch) wird ausgeschlossen. Das UN- Kaufrecht (CISG) ist nicht anwendbar.

		
	 4.      The place of jurisdiction for all disputes resulting from or in connection with this agreement shall be
to extent legally permissible - Munich.
	  	 4.      Gerichtsstand für alle Streitigkeiten aus oder im Zusammenhang mit diesem Vertrag ist - soweit
gesetzlich zulässig - München.

		
	 5.      In case single provisions of this Agreement are invalid or not enforceable, the further parts as a whole
shall remain effective. The invalid or unenforceable provision shall be replaced by such provisions which permissibly come nearest to the economic effect intended by the invalid or not executable provisions. The same shall apply if there is a gap in
the contractual provisions.
	  	 5.      Sollten einzelne Bestimmungen dieses Vertrages unwirksam oder nicht durchführbar sein, so bleiben
die übrigen Teile insgesamt wirksam. An die Stelle der unwirksamen oder undurchführbaren Bestimmungen treten solche, die den mit den unwirksamen oder undurchführbaren Bestimmungen verfolgten wirtschaftlichen Zwecken in zulässiger
Weise am nächsten kommen. Entsprechendes gilt beim Vorliegen einer Regelungslucke.

		
	 6.      Amendments require written form. This shall also apply to an amendment of this written form
clause.
	  	 6.      Änderungen bedürfen der Schriftform. Dies gilt auch für eine Änderung dieses
Schriftformerfordernisses.

		
	 7.      This Agreement has been prepared in both a German and an English version. The English version is
for
	  	 7.      Dieser Vertrag ist sowohl in englischer, als auch in deutscher Sprache verfasst. Die englische
Fassung

  

 –22/22– 

			
	 information purposes only. In a case of doubt, the German version shall prevail.
	  	 dient nur Informationszwecken. Im Zweifel ist die deutsche Fassung des Vertrags maßgeblich.

		
	 8.      Each Party bears its own costs. The Purchaser shall in particular bear attorneys’ costs charged by
the law firm Holme Roberts & Owen, Rosental 3-4, 80331 Munich, in connection with this Agreement up to an amount of EUR 25,000.00 plus VAT after receipt of an invoice.
	  	 8.      Jede Partei trägt ihre eigenen Kosten. Der Käufer trägt insbesondere die von der Kanzlei
Holme Roberts & Owen, Rosental 3-4, 80331 München, berechneten Anwaltskosten im Zusammenhang mit diesem Vertrag in Höhe von bis zu EUR 25.000,00 zuzüglich Mehrwertsteuer nach Erhalt einer Rechnung.

		
	SEC. 13	  	 §13  

	CONDITION PRECEDENT	  	AUFSCHIEBENDE BEDINGUNG
	 This Agreement is concluded subject to the conditions precedent of the consent by the supervisory board of GPC Biotech AG. The Purchaser shall give the written
consent of the supervisory board of GPC Biotech AG (signed by the chairman of the supervisory board or the vice chairman) to the Seller. If the Seller is not in the possession of this consent by Friday, March 4, 2005 16h, this Agreement shall
be invalid.
	  	 Dieser Vertrag wird unter der aufschiebenden Bedingung der Zustimmung des Aufsichtsrates der GPC Biotech AG abgeschlossen. Die schriftliche Zustimmung des
Aufsichtsrates der GPC Biotech AG (unterzeichnet durch den Aufsichtsratsvorsitzenden oder dessen Stellvertreter) hat der Käufer dem Verkäufer zu übergeben. Liegt dem Verkäufer diese Zustimmung nicht bis spätestens Freitag,
4. März 2005 16:00 Uhr vor, ist dieser Vertrag gegenstandslos.

  

					
	IN WITNESS WHEREOF, the parties have duly executed this Agreement as of the date first above written.	 		 	ZUM ZEUGNIS DESSEN haben die Vertragsparteien diese Vereinbarung am obigen Datum unterschrieben.
			
	Munich/München, 02,Märch 2005	 		 	Munich/München, 2, März 2005
			
	Seller Verkäufer	 		 	Purchaser / Käufer
			
	/s/ Dr. Joseph Füchsl	 		 	/s/ Dr. Elmar Maier
	 Dr. Joseph Füchsl
 Insolvency Receiver
(Insolvenzverwalter)
	 		 	 Dr. Elmar Maier
 Managing Director /
Geschäftsführer

  

 –23/23– 

 Table of Exhibits/Verzeichnis der Anlagen 
  

					
	 Exhibit/Anlage
	  	 Title of Exhibit
	  	 Bezeichnung der Anlage

			
	 A
	  	Ruling on the Opening of the Insolvency Proceedings	  	Beschluss über die Eröffnung des Insolvenzverfahrens
			
	 1.2(1)
	  	Intellectual Property included in the Assets	  	Geistiges Eigentum, das zu den Assets gehört
			
	 1.2(2)
	  	Intellectual Property excluded from the Assets	  	Geistiges Eigentum, das nicht zu den Assets gehört
			
	 1.3
	  	Agreements	  	Verträge
			
	 1.10
	  	Grants	  	Fördermittel
			
	 8.3
	  	Assignment Agreement Insolvency Estate Loan	  	Abtretungsvereinbarung Massedarlehen
			
	 9.1(1)
	  	Employees intended to be taken over	  	Arbeitnehmer, die übernommen werden sollen
			
	 9.1(2)
	  	Employees not intended to be taken over	  	Arbeitnehmer, die nicht übernommen werden sollen
			
	 11
	  	Approval by Creditors’ Committee	  	Zustimmung des Gläubigerausschusses

  

 –24/24–

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00101-of-00352.parquet"}]]